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Abstract  
Background: Sepsis is a lethal condition that causes organ dysfunction due to a dysregulated 
host response to an infection. It is one of the leading causes of morbidity and mortality 
globally with approximately 6 million deaths occurring every year. Transfusion-associated 
sepsis (T-AS) can occur through the transfusion of contaminated blood components, 
commonly platelet concentrates (PCs). The “cytokine storm” is thought to be the main 
pathophysiology behind sepsis and the cytokines secreted within bacterial contaminated PCs 
could play a key role in the development of T-AS in recipients. This study investigated the 
effect of bacterially-primed platelet releasates on the activation status of neutrophils and 
monocytes, with the aim of understanding the link between platelet product contamination, 
the cytokine storm, and the severity of clinical symptoms in transfusion recipients. Findings: 
The cytometric bead array assay demonstrated that RANTES was significantly elevated in 
comparison with IL-1β, IL-6, and TNF-α when platelet rich plasma samples were incubated 
with planktonic and biofilm forms of Staphylococcus epidermidis and Serratia marcescens. 
Flow cytometric analysis of the surface markers CD54, CD11b and CD66b on U937 and HL-60 
cell lines demonstrated no changes in expression when treated platelet releasates that had 
been primed with S. epidermidis and wild type (WT) Escherichia coli. Yet treating these cells 
with platelet releasates primed with multi-resistant E. coli (planktonic or biofilm form) caused 
a highly significant upregulation in CD54 expression. Platelet-free plasma alone was found to 
cause a degree of upregulation of all three surface markers in some cases suggesting minor 
immunomodulatory activity of plasma proteins. Despite its significant release from 
bacterially-primed platelets, recombinant RANTES (rhRANTES) at different concentrations did 
not induce significant changes in surface expression of the activation markers on U937 and 
HL-60 cells however, variable effects on CD54 and CD11b expression were seen on primary 
human neutrophils. Curiously, CD66b appeared to be downregulated with increasing 
exogenous rhRANTES concentration. Conclusions: The results may indicate that RANTES 
requires synergy with additional cytokines/chemokines in order to induce activation of 
neutrophils and monocytes and cannot act in isolation. Bacterial virulence appears to play a 
role in the resultant cytokine profiles of platelets evidenced by the stark difference in cell 
activation caused by multi-resistant E. coli-primed platelets in comparison with WT E. coli and 
S. epidermidis. 
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1.0 Introduction 
 
1.1 Sepsis: Definition and Significance 
Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host 
response to infection (Singer et al., 2016). It is estimated to affect over 30 million people 
globally with 6 million cases leading to death every year (Fleischmann et al., 2016). This is 
more than the deaths caused by bowel, breast and prostate cancer combined (Sepsis Trust, 
2019). Despite extensive research to elucidate the pathophysiology and potential treatments 
for sepsis, it remains as one of the leading causes of mortality and morbidity worldwide, 
affecting over 35% of hospitalised patients in Europe alone, and with increasing incidence 
(Vincent et al., 2006). Increased incidence could also be due to the increased awareness 
within secondary healthcare settings and the improved disease coding for sepsis. However, 
many cases go unreported, especially in low economic countries, which bears the highest 
sepsis burden (Reinhart et al., 2017), and so statistics on sepsis incidence are likely to be 
significantly underestimated.  
 
It must be emphasised that although infection is the triggering event for sepsis, it is ultimately 
the dysregulated immune response involving concomitant pro- and anti-inflammatory 
responses that results in pathophysiology even after successful treatment of the infection 
(van der Poll et al., 2017). The hyperinflammation of sepsis involves the activation of 
pathogen associated molecular patterns (PAMPs) and/or damage associated molecular 
patterns (DAMPs) which initiates the immune response, this is accompanied by the activation 
of the coagulation cascade and may result in disseminated intravascular coagulation (DIC) and 
multiple organ failure as well as leucocyte exhaustion (Boomer et al., 2014). The extent of the 
hyperinflammatory phase is dependent on the patient’s comorbidities, the causative agent, 
the bacterial load and genetic factors, both of the pathogen and host (Boomer et al., 2014). 
Subsequent immunosuppression may develop in the efforts to control the excessive 
inflammatory response. However, this puts the patient at risk of developing reoccurring, 
secondary and nosocomial infections and difficulties in eradicating infection (Delano and 
Ward, 2016). The immunosuppressive phase is thought to be caused by Treg cells (Hotchkiss 
et al., 2013). A summary of the consequences of hyper- and hypo-inflammation in sepsis is 
described in Fig. 1.  
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Figure 1: Sepsis is triggered by the recognition of bacteria by immune cells resulting in 
excessive secretion of proinflammatory cytokines and subsequent significant leucocyte 
activation and trafficking, complement activation and a pro-coagulatory state which may 
result in DIC tissue ischaemia thus organ failure. To counteract the effects of inflammation, 
anti-inflammatory cytokines may be secreted in an effort to return to homeostasis however, 
consequences of this results in impaired leucocyte effector function and apoptosis as well as 
the proliferation of Treg cells to inhibit leucocyte activation. This predisposes patients to 
opportunistic infections. Adapted from Faix, 2013. 
 
  
 4 
As a heterogenic syndrome, symptoms of sepsis vary from individual-to-individual and are 
nonspecific, but generally patients present with fever, tachycardia, altered mental status, 
hypotension and dyspnoea (Levy et al., 2003). One study identified a link between the number 
of dysfunctional organs and mortality in emergency department patients leading to the 
development of the Sequential (sepsis-related) Organ Failure Assessment (SOFA) score (Table 
1) to predict the clinical outcome and severity of organ failure in sepsis patients (Vincent et 
al., 1996; Shapiro et al., 2006). The SOFA has been validated as a good method for risk 
stratification and predictor of patient prognosis (Jones et al., 2009). Around 15% of sepsis 
survivors die within a year of hospital discharge followed by 6-8% of patients dying per year 
over the subsequent 5 years (Shankar-Hari et al., 2019). Those who do survive may suffer 
from post-sepsis syndrome which refers to the temporary or permanent physical and 
psychological complications that patients may experience (Tiru et al., 2015). These include 
decreased cognitive function, chronic fatigue, difficulty sleeping, functional disability and 
poor concentration; this in turn, is associated with the development of mental health issues 
such as depression and post-traumatic stress disorder (Tiru et al., 2015; Huang et al., 2018).  
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Table 1. The Third International Consensus Definition for Sepsis and Septic Shock (Sepsis-3) 
presented the SOFA score as a mean to determine the extent of organ failure of patients with 
sepsis. Abbreviations: FIO2 – fraction of inspired oxygen; MAP –mean arterial pressure; PaO2 
– partial pressure of oxygen. aAdapted from Vincent et al., 1996. bCatecholamine doses are 
given as µ/kg/min for at least 1 hour. cGlasgow Coma Scale scores range from 3 – 15; higher 
score indicates better neurological function.  
 Score     
Organ System 0 1 2 3 4 
Respiration 
PaO2/FIO2, 
mm Hg (kPa) 
≥ 400 (53.3) < 400 (53.3) < 300 (40) < 200 (26.7) 
with 
respiratory 
support 
< 100 (13.3) 
with respiratory 
support 
Coagulation 
Platelets, 
x 103/µL 
≥ 150 < 150 < 100 < 50 < 20 
Liver 
Bilirubin, 
mg/dL 
(µmol/L) 
< 1.2 (20) 1.2 – 1.9 
(20 - 32) 
2.0 – 5.9 
(33 - 101) 
6.0 – 11.9 
(102 - 204) 
> 12.0 (204) 
Cardiovascular 
 MAP ≥ 70 
mm Hg 
MAP < 70 
mm Hg 
Dopamine  
< 5  
or 
dobutamine 
(any dose)b 
Dopamine  
5.1 – 15  
or  
epinephrine  
≤ 0.1  
or 
norepinephrine 
≤ 0.1b 
Dopamine  
> 15  
or  
epinephrine  
> 0.1  
or 
norepinephrine 
> 0.1b 
Central Nervous System 
Glasgow Coma 
Scale scorec 
15 13 – 14 10 – 12 6 – 9 < 6 
Renal 
Creatinine, 
mg/dL  
(µmol/L) 
< 1.2 (110) 1.2 – 1.9 
(110 - 170) 
2.0 – 3.4 (171 
- 299) 
3.5 – 4.9 (300) 
- 440 
> 500 (440) 
Urine Output, 
mL/d 
   < 500 < 200 
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1.2 Sepsis and the Cytokine storm 
Cytokines are a group of proteins released by various cell types and function as intracellular 
signalling molecules. Cytokines can be grouped into several categories based on their function 
and structure but most cytokines have overlapping or duel functions (Tisoncik et al., 2012). 
Some of these include tumour necrosis factor (TNF), interleukins (IL) and chemokines. TNF-α 
is one of the most extensively studied cytokines and is known for its prominent role within 
inflammation and is central in the occurrence of the “cytokine storm” and other inflammatory 
diseases (Idriss and Naismith, 2000). The main role of interleukins is in the differentiation and 
activation of leucocytes where they can exhibit pro- or anti-inflammatory roles (Tisoncik et 
al., 2012). Chemokines can be divided into four subfamilies based on the placement of the 
first two cysteine residues (CXC, CX3C, C and CC) and are vital in the recruitment of specific 
immune cells (Ono et al., 2003).  
 
The pathophysiology of sepsis remains to be fully elucidated but one of the main accepted 
ideas is the “cytokine storm” that is responsible for the immunopathology seen in sepsis. 
Currently, there is no clear definition of what exactly constitutes the “cytokine storm” but the 
general concept is an excessive or uncontrolled released of proinflammatory and anti-
inflammatory cytokines (Tisoncik et al., 2012). The initial phase of sepsis is acute inflammation 
in which the initial insult produces a local inflammatory response in which cytokines secreted 
may “spillover” into the systemic circulation leading to the priming of leucocytes and 
amplification of inflammation; this will rapidly become independent of any stimuli coming 
from the invading pathogen (Chousterman et al., 2017). The later phase of sepsis is 
immunosuppression or compensated anti-inflammatory response syndrome, caused by the 
over secretion of anti-inflammatory cytokines such as interleukin-10 (IL-10) and as a 
consequence, many activated immune cells go through anergy and apoptose, leaving the 
patient vulnerable to secondary infections (Jacobi, 2002). 
 
1.3 Transfusion-Associated Sepsis and Transfusion-Associated Bacterial Infection   
Transfusion-associated bacterial infection (T-ABI) arises from the transfusion of bacterial 
contaminated blood products and is one of the biggest problems in transfusion medicine 
(Wilson-Nieuwenhuis et al., 2017). Platelet concentrates (PCs) are particularly susceptible to 
bacterial contamination due to their storage conditions of high glucose and ambient (22oC – 
 7 
24°C) temperatures, which are ideal for bacterial growth; this in turn limits the shelf life of 
PCs to 5-7 days (Hong et al., 2016). The source of contamination can be attributed to the 
venepuncture site, the presence of donor bacteraemia and whole blood processing 
(Blajchman et al., 2005). The National Health Service Blood and Transplant (NHSBT) in England 
introduced routine screening of PCs in 2011 using an automated microbial detection system 
known as the BacT/ALERT® to ensure that contaminated PCs are effectively identified and 
withdrawn from stock (McDonald et al., 2017).  Screening is performed 6 h after donation 
and if the sample is culture negative, the blood product is released to hospitals labelled as 
“negative to date”. The test aliquot remains within the Blood Centre for continuous 
BacT/ALERT® testing throughout the 7-day shelf life of the platelet product. If at a later time 
point, the aliquot flags as culture positive, the unit is either recalled, or if it has already been 
transfused, the patient is identified and treated with the most appropriate antibiotic regime.  
Like conventional sepsis, transfusion-associated sepsis (T-AS) occurs when there is a 
dysregulated host response to the bacterial infection, leading to organ dysfunction. The 
reported incidence of T-AS is likely to be an underestimate, as many PC recipients are 
leucopenic and/or immunosuppressed therefore, if the patient were to exhibit septic 
episodes, it is unlikely that the physician would suspect platelet transfusions as the cause 
(Blajchman and Goldman, 2001). In addition to this, symptoms of septic transfusion reactions 
broadly overlaps with other non-infectious transfusion reactions such as febrile non-
haemolytic transfusion reactions, transfusion-associated circulatory overload and 
transfusion-associated acute lung injury (Hong et al., 2016). If the recipient is also taking 
antibiotics, it could partially mask the symptoms associated with sepsis (Kuehnert et al., 2001).  
Under-detection of bacterially contaminated platelet units within the NHSBT centres could 
also contribute to the low reported incidences of TA-S. The initial low bacterial inoculum or 
the formation of biofilms can both lead to false negative results from the BacT/ALERT® system 
(Murphy et al., 2008), Biofilms are microbial communities adhered onto biotic or abiotic 
surfaces and are encased within an extracellular polymeric substance (EPS) (Hoffman et al., 
2005; Dong et al., 2018). Bacterial cells within biofilms typically undergo phenotypic and 
genotypic changes, leading to altered cell growth which can bypass screening systems which 
rely on the production of CO2 from respiring bacteria for detection (Benjamin and Wagner, 
2007). Furthermore, the presence of biofilms in the original blood bag may decrease the 
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number of planktonic bacteria available for aliquoting into the test vials, resulting in false 
negatives and increased risk of T-BI and T-AS (Wilson-Nieuwenhuis et al., 2017).  
 
The severity of T-ABI is dependent on the causative bacteria with Gram negative species 
tending to cause more fatal reactions (60% of cases compared to Gram positive species) due 
to the presence of lipopolysaccharides in their cell wall (Kuehnert et al., 2001; Védy et al., 
2009). Gram positive organisms on the other hand, are the predominant bacterial 
contaminants of blood products, especially commensals of the skin flora, with Staphylococcus 
epidermidis and Propionibacterium acnes being the most commonly isolated bacteria (Greco 
et al., 2007). Gram negative microorganisms implicated in T-AS and T-ABI include Serratia spp., 
Salmonella spp., Pseudomonas spp., Enterobacter spp. and Escherichia coli (Védy et al., 2009). 
The conditions of collection, preparation and storage of the different blood components 
constitute a broad range of environments that may select a specific bacterial species, 
subpopulation or even distinct multispecies consortia (Desroches et al., 2018).  
 
1.4 Staphylococcus epidermidis 
S. epidermidis is a Gram positive, coagulase-negative, normal skin flora bacterium and is a 
major causative agent in T-ABI and T-AS (Greco et al., 2007). Despite the use of disinfectant 
wipes to sterilise the phlebotomy site, S. epidermidis has still been found adhered firmly onto 
the donors’ arm hairs enabling it to cause infection after wound entry (Mase et al., 2000). The 
opportunistic pathogen was shown to display a slow-growth rate in PCs compared to other 
bacteria resulting in false negatives during screening (Brecher et al., 2000; Mohr et al., 2006). 
The pathogenesis of S. epidermidis is largely related to its ability to form biofilms, several 
studies have shown that even non-biofilm forming strains are able to switch to a biofilm 
phenotype within PCs (Greco et al., 2007; Greco-Stuwart et al., 2012; Loza-Correa et al., 2019). 
The switch between strains exhibiting a biofilm-negative phenotype to a biofilm-positive 
phenotype was hypothesised to be due to antimicrobial peptides (AMPs) present within the 
PCs triggering a survival mechanism in S. epidermidis cells (Loza-Correa et al., 2019). It is 
proposed that the trigger initiates pathways in which metabolism and cell growth are 
significantly reduced to reserve energy and, in the process, there is upregulation of virulence 
genes such as those involved in biofilm formation, as biofilms confer protection from 
antimicrobial agents (Hodgson et al., 2014; Ali et al., 2014). Platelets themselves are also 
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thought to play a role in biofilm formation as they can act as a scaffold for the primary 
attachment of S. epidermidis cells through the polysaccharide intracellular adhesin (PIA) (Ali 
et al., 2014; Loza-Correa et al., 2019). A study found that strains that have a fast growth rate 
produced less biofilms compared to strains with a slow growth rate (Ali et al., 2014). This 
observation could be interpreted as that slow growing strains are not slow-growing per se, 
but rather have more growth associated with the biofilm than planktonic cells (Ali et al., 2014). 
 
1.5 Serratia marcescens  
S. marcescens is a facultative anaerobe found in various environments such as soil, bodies of 
water, plants and animals (Cristina et al., 2019). It is also a commensal of the human 
gastrointestinal tract and was once thought to be non-pathogenic to humans due to its low 
virulence (Ramírez-Acros et al., 2006). Colonies of this bacterium can be identified by 
production of the pigment prodigiosin (red) and is thought to be associated with increased 
growth compared to non-prodigiosin producing strains (Haddix and Shanks, 2018). The role 
of S. marcescens as an opportunistic pathogen was brought to light after being found as the 
causative agent for the T-AS epidemic in 1991 in Denmark and Sweden (Heltberg et al., 1993; 
Högman et al., 1993). The epidemic occurred as a result contamination of the blood bags 
during the cooling step of the manufacturing process, this led to the subsequent transfusion 
of S. marcescens resulting in three fatalities (Heltberg  et al., 1993; Högman et al., 1993; 
Szewzyk et al., 1993; Roth et al., 2000). The material of the blood bags, polyvinylchloride, was 
thought to contribute to the survival of S. marcescens as it permits the evaporation of fluids 
creating a humid environment in which the pathogen thrives (Heltberg et al., 1993). 
Countermeasures were implemented to prevent such contaminations through the use of 
oxygen and water reduction technologies and ventilated with nitrogen to prevent the growth 
of aerobic microorganisms (Högman et al., 1993). However, this technique has no effect on S. 
marcescens as it is a facultative anaerobe (Högman et al., 1993).  
 
The ubiquitous nature of S. marcescens contributes to its adaptability and its survival within 
healthcare environments and as such, it can be found in sinks, soap dispensers, disinfectants 
and medical apparatuses making it difficult to fully eradicate (Dessi et al., 2009). As a 
consequence, transmission of S. marcescens can occur through the hands of healthcare 
workers leading to nosocomial infections; most noticeably 16% of Gram negative bacteraemia 
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cases within the neonatal intensive care unit (Stock et al., 2003; Arslan et al., 2010; Voelz et 
al., 2010; Greco-Stewart et al., 2012). In addition to its ability to survive within hostile 
environments, studies have shown that strains of S. marcescens possess R factors which are 
plasmids that encode for the resistance to multiple antibiotics, adding to the difficulty of 
eradicating this pathogen (Stock et al., 2003; Dessi et al., 2009). Other studies have also 
demonstrated that S. marcescens is able to resist phagocytosis which may explain its survival 
within blood components (Högman et al., 1993). Serratia spp. has also been reported to 
remain culture negative even after 9 days of storage in PCs (Ramírez-Acros et al., 2006).  
 
1.6 Escherichia coli 
The main reservoir of the Gram negative E. coli is the gastrointestinal tract of humans and 
animals in which horizontal transfer of plasmids occur, leading to high numbers of genetically 
variable populations and pathogenicity (Desroches et al., 2018). E. coli can be divided into 
four phylogenetic groups: A, B1, B2 and D in which groups B2 and D are the most highly 
virulent strains, whilst groups A and B1 are generally considered commensals (Jauréguy et al., 
2007). The opportunistic pathogen is able to translocate from the intestines to the 
bloodstream causing bacteraemia and extra-intestinal infections which often precedes sepsis; 
donors may often present with an asymptomatic bacteraemia at the time of donation 
(Conceição et al., 2012; Mosavie et al., 2019). The origin of E. coli bacteraemia in donors is 
most commonly caused by urinary tract infections as inflammation of the urinary tract 
promotes the translocation of E. coli from the bladder to the bloodstream (Desroches et al., 
2018). In 20% of cases of bacteraemia, E. coli was the most prevalent isolate and accounted 
for 17% of septic episodes in 2001 in the USA, resulting in 40, 000 deaths (Jauréguy et al., 
2007).  
 
Within PCs, the abundance of AMPs (mostly released by the platelets themselves), antibodies 
and complement proteins provides a harsh environment for bacteria to survive in (Taha et al., 
2016). As E. coli continually alternates between its niches, i.e. the intestines of vertebrates 
and the outside environment, its versatility enables it to colonise new niches and generates 
a population that survive optimally in PCs (Bleibtreu et al., 2013). These strains when 
transfused have often gained serum resistance, which proves to be highly advantageous for 
it to cause infection within the recipient, and thus T-ABI/T-AS occurs (Desroches et al., 2018). 
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Iron availability was also thought to be partly responsible for the selection of T-ABI/T-AS 
strains as it was demonstrated that implicated strains grew rapidly in the anticoagulant citrate 
solution of PCs where iron was limited since iron sustains bacterial growth during infection 
(Desroches et al., 2018; Johnsen et al., 2019). Another issue with citrate solutions is that a 
low abundance of iron within the solution selects for strains that over express siderophores, 
this characteristic is commonly associated with many T-ABI strains, including E. coli 
(Desroches et al., 2018; Gravemann et al., 2019). As E. coli is one of the leading causes of 
Gram negative bacteraemia due to its ability to translocate from the host’s intestines, the 
health status of donors along with follow-ups post donation should be implemented to detect 
clinical signs of bacteraemia to minimise the risks of PC contamination (Desroches et al., 2018). 
 
1.7 Innate Immunity 
Innate immunity is the first line of defence against infection, consisting of anatomic barriers, 
humoral factors and cellular components, until the more specific adaptive immunity is 
activated. Harmful stimuli will trigger an inflammatory response involving the migration of 
leucocytes to the injured or infected area, vasodilation of the blood vessels and secretion of 
proinflammatory mediators. Initiation of the innate response requires the recognition of 
PAMPs or DAMPs by pathogen recognition receptors (PRRs) found on various innate cells 
(neutrophils, monocytes, macrophages, dendritic cells etc.). Recognition of PAMPs and/or 
DAMPs will trigger downstream signalling pathways for pathogen clearance and wound repair 
(Jiang et al., 2007). However, excessive inflammation can lead to a number of chronic 
inflammatory diseases and SIRS. On the other hand, inadequate inflammation will result in 
persistent infections and compromised wound healing. Therefore, a balance between hyper- 
and hypo-inflammation is necessary in the development and resolution of a normal immune 
response to infection. 
 
Activation of the inflammatory response is mediated by a multiprotein complex, called the 
inflammasome, which promotes the secretion of IL-1 and IL-18 by activated macrophages, 
monocytes and platelets (Martinon et al., 2002). The inflammasome is composed of several 
NOD-like receptor (NLR) proteins (NALP1, NLRP3 and NLRC4), the ASC adaptor molecule, and 
caspase-1 and -5 (Martinon et al., 2002). Upon stimulation by microbial factors or 
endogenous signals through the recognition by the NLR family proteins, there is an increased 
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production of pro-IL-1 and pro-IL-18 (inactive forms of IL-1 and IL-18) (Kumar, 2018). 
Caspase-1 is self-activated via self-cleavage leading to proteolytic activity on pro-IL-1 and 
pro-IL-18 and subsequent secretion of IL-1 and IL-18 (Guo et al., 2015). Both 
proinflammatory cytokines are then able to exert their effect and recruit inflammatory cells 
to the site of injury or infection leading to a positive feedback mechanism in which various 
other proinflammatory cytokines and chemokines are secreted (Martinon et al., 2002).  
 
Migration of circulating leucocytes to the chemotactic gradient established involves tightly 
coordinated interactions between the leucocyte and the endothelium in three steps. The first 
step is margination and rolling which involves the low-affinity interaction between L-selectin 
constitutively expressed on leucocytes and P-selectin glycoprotein ligand-1 (PSGL-1), and E- 
and P-selectin on endothelial cells upregulated by inflammatory stimuli. This reversible 
adhesion allows the leucocytes to roll along the vasculature towards the inflamed site (Alves-
Filho et al., 2010). The next step is the firm adhesion between the leucocytes and the 
endothelial cells via 2 integrin (CD11b/CD18) and their respective receptors; intracellular 
adhesion molecule 1 (ICAM-1/CD54) and vascular cell adhesion molecule 1 (VCAM-1/CD106) 
(von Hundelshausen and Weber, 2007). This initiates the activation of leucocytes and L-
selectin shedding for the transition from rolling to firm adhesion (Hafezi-Moghadam et al., 
2001; Shen et al., 2017). Following firm adhesion, the cytoskeleton of the leucocyte is 
rearranged to an amoeba-like state allowing leucocytes to pass through the tight junctions of 
endothelial cells and extravasate into the interstitial fluid (Alves-Filho et al., 2010). 
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Figure 2: Steps involved in leucocyte transmigration. 1) Inflammation activates the 
endothelium to express adhesion molecules, E- and P-selectin, ICAM-1 and VCAM-1 along 
with secretion of cytokines and chemokines for leucocyte recruitment. 2) Rolling involves 
weak interactions between L-selectin and PSGL-1 on leucocytes to E- and P-selectin on 
endothelial cells. 3) The β2 integrin on leucocytes binds to ICAM-1 or VCAM-1 on endothelial 
cells with a strong affinity causing arrest and subsequent crawling along the vasculature 
before extravasation. 4) The leucocyte releases proteolytic enzymes to digest through the 
basement membrane allowing it to enter the site of inflammation to perform its effector 
functions. Subsequent cytokine and chemokine release (dashed arrows) by the leucocyte 
sustain recruitment of leucocytes. Adapted from Schooner and Parkos, 2008.  
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1.7.1 Neutrophils 
Neutrophils are phagocytic, polymorphonuclear cells characterised by their distinctive multi-
lobed nuclei and are the most abundant circulating leucocytes. They possess an arsenal of 
antimicrobial factors such as neutrophil extracellular traps (NETs), proteolytic enzymes and 
reactive oxygen species (ROS) to aid in pathogen clearance (Shen et al., 2017). Playing an 
essential role in innate immunity, they are the first cells to respond to inflammatory stimuli 
and the control of an infection depends on their efficiency to transmigrate (Fig. 2). Failure to 
eradicate the invasive pathogen would lead to its systemic spread resulting in sepsis. In septic 
conditions, neutrophil effector functions are impaired along with altered chemotactic activity 
(Sônego et al., 2016). Nitric oxide (NO), synthesised by inducible-nitric oxide synthase (iNOS) 
in leucocytes, is a molecule with cardiovascular, immunomodulatory and neuronal properties 
and is responsible for the bactericidal activity of neutrophils (Wolkow, 1998). However, its 
overproduction has been shown to contribute to the pathogenesis of septic shock, 
demonstrated by significant vasodilation and subsequent hypotension, hyporesponsiveness 
to vasopressors, and organ damage (Petros et al., 1994). Several studies have also 
demonstrated the inhibitory effects of NO on neutrophil chemotaxis along with the 
proinflammatory cytokines, TNF-, macrophage-derived neutrophil chemotactic factor 
(MNCF), IL-1 and IL-8 by decreasing the adhesiveness of neutrophils to the endothelium 
(Tavares-Murta et al., 1998; Benjamim et al., 2000; Benjamim et al., 2002). 
 
The IL-8 chemokine receptor, CXCR2, found on the surface of neutrophils is also critical for 
neutrophil migration and its expression is regulated by the PRR, toll-like receptor-2 (TLR-2) 
and TLR-4 (Eash et al., 2010). Recognition of bacterial peptidoglycan and lipopolysaccharide 
by TLR-2 and TLR-4 respectively leads to the activation of the GRK2 pathway and resultant 
internalisation of CXCR2 on neutrophils; this mechanism is important to keep the neutrophils 
within the infectious loci to eliminate invasive pathogens (Alves-Filho et al., 2009). However, 
in septic conditions CXCR2 is significantly downregulated which may be due to the effect of 
simultaneous release of pro- and anti-inflammatory cytokines as well as the overstimulation 
of the TLRs leading to desensitization of CXCR2 thus defective neutrophil migration (Van Der 
Meeren et al., 1999; Benjamim et al., 2000; Souto et al., 2011). In addition to this, patients 
with sepsis have been observed to have significant serum soluble L-selectin levels, likely due 
to the increased L-selectin shedding in response to the uncontrolled systemic inflammation 
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(Ferri et al., 2009). Consequently, neutrophils are strongly adhered onto the endothelium and 
sequester within the vascular compartment causing tissue ischaemia and organ dysfunction 
(Lerman and Kim, 2015).  
 
Other effector functions of neutrophils observed to be suppressed are ROS production and 
phagocytosis (Kaufmann et al., 2006). Impaired phagocytosis could be explained by 
desensitisation of CD64 (human IgG receptor FcγRI) under excessive inflammatory conditions, 
a receptor that is responsible for phagocytic activity (Shen et al., 2017). On the contrary, NET 
release appears to be upregulated in sepsis due to metabolic changes induced in sepsis and 
is correlated with severe organ dysfunction. It is thought that NET can mediate the vascular 
endothelium damage via myeloperoxidase activity and promote thrombus formation, as it 
can provide a scaffold for platelets and erythrocytes to attach (Shen et al., 2017). 
 
1.7.2 Monocytes/Macrophages 
Monocytes are mononuclear, phagocytic cells which can differentiate into macrophages, 
osteoclasts or dendritic cells depending on their microenvironment (Cavaillon and Adib-
Conquy, 2005). The main role of monocytes in the absence of infection is the removal of 
apoptotic cells and cellular debris. During infection, they are the one of the first responders, 
alongside neutrophils, in the control of pathogens and are a source of inflammatory cytokines 
such as TNF-, IL-1 and IL-1 (Cavaillon and Adib-Conquy, 2005). Macrophages can act as a 
bridge between the innate and adaptive immune response through antigen presentation.  
 
Similarly to neutrophils, the effector functions of monocytes/macrophages are also impaired 
in sepsis in which their capacity to produce proinflammatory cytokines are diminished along 
with decreased antigen presentation (Sinistro et al., 2008). Monocyte recruitment was also 
observed to be reduced as a consequence of downregulation of CCR5 (receptor for the 
monocyte chemotactic protein) expression through TLR-2 signalling (Souto et al., 2011) (Fig. 
2).  As patients progress into the immunosuppressive phase of sepsis, monocytes adopt the 
immunosuppressive phenotype where they are unable to respond to secondary infections, 
and patients are at increased risk of morbidity and mortality (Drewry et al., 2018). This 
phenomenon could be explained by monocytes gaining lipopolysaccharide (LPS) tolerance 
following challenge induced by the transcription factor, hypoxia inducible factor-1 (Ertel et 
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al., 1995; Salomao et al., 2002; Shalova et al., 2015). However, studies have shown that 
monocytes still possess phagocytic abilities and other antimicrobial activities as well as tissue 
repair in septic patients (Shalova et al., 2015; Santos et al., 2016). This suggests that rather 
than suppression of genes involved in effector functions, monocytes are “reprogrammed” 
due to the multitude of stimuli occurring in sepsis (Shalova et al., 2015). In support of this, 
Tang et al. failed to identify a strict pro- or anti-inflammatory phenotype at a genomic level 
and suggested that leucocytes exhibit both pro- and anti-inflammatory phenotypes 
simultaneously.  
 
Secretion of proinflammatory cytokines and activation of the adaptive immunity requires the 
ligation between CD40 and CD40 ligand (CD40L) leading to the increased expression of 
surface CD80 and CD86 for T cell activation (Sinistro et al., 2008). Monocytes isolated from 
patients with sepsis displayed an inability to activate CD40L and therefore failure to induce T 
cell effector functions (von Müller et al., 2006). Instead, monocytes undergo spontaneous 
apoptosis or anergy due to the absence of costimulatory signals through T cell interactions 
(Sinistro et al., 2008). In addition, isolated monocytes from sepsis patients show a markedly 
reduced expression of Human Leucocyte Antigen – DR isotype (HLA-DR), a complex critical in 
antigen presentation. This reduced expression is associated with poor prognosis in sepsis 
(Hotchkiss et al., 2013). The mechanism behind this event is currently still under investigation 
however, one theory suggests that sustained secretions of anti-inflammatory cytokines such 
as IL-10 and transforming growth factor-1 (TGF-1) may inhibit the expression of HLA-DR 
(Monneret et al., 2004).  
 
1.8 Platelets 
Platelets are anucleate fragments of megakaryocytes essential for the maintenance of 
haemostasis. Deviation from the norm will trigger the coagulation cascade to prevent blood 
loss and to preserve vascular integrity. Individuals with haematological or oncological 
disorders may suffer from thrombocytopenia as a complication of the disease and would 
require platelet transfusions to alleviate symptoms (Wilson-Niewenhuis et al., 2017). 
Recently, significant attention has focused on the role of platelets in innate immunity, rather 
than solely considering these cells as “blood clotters”. The discovery that platelets express all 
ten TLR transcripts implies that platelets have the ability to recognise PAMPs on invading 
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microorganisms (Akinosoglou and Alexopoulos, 2014). It has since been shown that 
recognition of PAMPs leads to platelet activation, release of AMPs and secretion of a variety 
of cytokines and chemokines from platelet -granules that act to coordinate immune 
responses. In addition to this, platelets were also shown to have phagocytic properties in 
which immunohistochemical staining revealed Staphylococcus aureus were contained within 
a vacuole, similar to a phagosome in phagocytes, after incubation (Youssefian et al., 2002). 
However, the outcome of the internalised bacteria remains to be elucidated but it has been 
suggested that merging of the -granule and vacuole may facilitate bacterial killing 
(Youssefian et al., 2002; Hamzeh-Cognasse et al., 2018). It is possible that the combination of 
these abilities allows contaminated platelet units to self-sterilise as a result of bactericidal 
action during storage but their efficacy is still not clearly understood (Brecher, 2018).  
 
As one of the major sources of cytokine release, it is believed that platelets are a major 
contributor of the “cytokine storm” and uncontrolled activation in sepsis can lead to DIC and 
tissue ischaemia resulting in considerable platelet consumption and thus thrombocytopenia 
(Venkata et al., 2013). Production of non-specific, anti-platelet antibodies by B cells as well as 
cytokine-driven haemophagocytosis of platelets can also contribute to sepsis-induced 
thrombocytopenia (Venkata et al., 2013). Thrombocytopenia was shown to impair host 
defence leading to increased bacterial loads, which further implies that platelets have a role 
in innate immunity (Zhou et al., 2018). Administration of anti-platelet drugs such as aspirin 
and P2Y12 inhibitors, both of which are used extensively in patients to reduce the haemostatic 
function of hyperactive platelets, was shown to be beneficial in reducing mortality in sepsis 
patients (Thomas et al., 2015). Downregulation of P-selectin, inhibition of platelet-leucocyte 
aggregates, diminished prothrombotic activity and, most importantly, decreased secretion of 
cytokines and chemokines was observed following anti-platelet treatment in a human model 
of sepsis (Thomas et al., 2015). 
 
1.9 RANTES  
RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) is a 
proinflammatory chemokine responsible for activation and trafficking of T cells, dendritic cells, 
basophils, natural killer cells, eosinophils and monocytes (Bacon et al., 1995). The effects of 
RANTES on neutrophils is currently still under investigation as some studies have shown that 
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RANTES is able to activate neutrophils (Appay et al., 1999; Ajuebor et al., 2001; Ramakrishna 
and Cantin, 2018) while others reported that RANTES had no effect on neutrophil function 
(Schall et al., 1990; Rot et al., 1992; Proudfoot et al., 1996). It was first discovered that T cells 
and platelet -granules were the major sources of RANTES but it is now known to be secreted 
by other cells at lower levels such as endothelial cells, epithelial cells and osteoclasts (Mohs 
et al., 2017). Contrary to the evidence for a pro-inflammatory role for RANTES, other data 
suggest that RANTES inhibits the release of histamine and therefore halts the inflammatory 
response, instead shifting the cellular environment towards wound repair and healing (El-
Sharkawy et al., 2007). Nonetheless, these conflicting studies all suggest that platelets, as 
major contributors to the RANTES pool, have an important role in regulating the immune 
response.   
 
Pilot work from our research group (Wilson-Niewenhuis et al., 2018) has found that artificially 
contaminating platelets with bacteria (particularly in biofilm form) leads to the secretion of 
high concentrations of RANTES whilst other cytokines and chemokines (such as IL-1, TNF- 
and IL-6) remained relatively unaffected. Reasons for this selective upregulation and the 
significance of it remain to be elucidated. Elevation of RANTES was also reported in sepsis, 
correlating with infection severity, tissue damage and mortality (Cavaillon et al., 2003; von 
Hundelshausen et al., 2007; Koupenova et al., 2015).  
 
This upregulation of RANTES in response to the bacteria is in addition to the increased release 
of this chemokine due to storage of the platelets in the blood bank. Indeed, factors secreted 
by platelets during storage will accumulate over time with high levels of RANTES providing an 
indication of platelet activation or destruction (Boehlen and Clemeston, 2001). There is also 
a possible correlation between platelet counts and the level of RANTES present in stored 
platelet units (Klinger et al., 1995; Fujihara et al., 1999). The shelf life of platelet concentrates 
in the blood bank is 5-7 days, and the accumulation of RANTES within these products over 
this time period is sufficient to trigger febrile reactions in recipients. Furthermore, RANTES 
may work synergistically with other chemokines to promote the severity of transfusion 
reactions (Boehlen and Clemeston, 2001). 
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It is clear that contaminated platelet units can lead to the development of sepsis in the 
transfusion recipient. However, what is not clear is what pushes the recipient’s immune 
system in to overdrive, to produce such an exaggerated response to the infection. Since 
RANTES is released in large quantities from platelets in response to bacteria (Wilson-
Nieuwenhuis et al., 2018), and platelets are vital in promoting activation of other components 
of the innate immune system (von Hundelshausen and Weber, 2007), the role of RANTES in 
direct activation of such components warrants further investigation. From 2015 to 2018, 
there were 422 cases of suspected bacterial infections with 273 of these cases found to be 
negative for bacterial contamination (upon follow-up testing of the test aliquot), inconclusive, 
or due to late detection of bacteria upon further testing (SHOT, 2015; SHOT, 2016; SHOT, 
2017; SHOT, 2018). This indicates that sepsis is largely an immunological pathology rather 
than bacterially driven. Research within this area would clarify the significance of RANTES in 
immunological responses to bacterial infections, and may add further weight to the use of 
RANTES as a marker for monitoring severity of immunological reactions. Further, it may 
highlight its use as a therapeutic target in patients with T-ABI/T-AS. 
 
1.10 Aim 
 
The aim of this project is to establish the effects of platelet releasates on neutrophil and 
monocyte responses, thereby contributing to a deeper understanding of the mechanism 
behind the link between bacterially contaminated platelet transfusions and infection/sepsis 
severity in transfusion recipients. 
 
1.11 Objectives  
 
 Determine the cytokine/chemokine profile being released from platelets in response 
to different microorganisms. 
 Determine the effects of the platelet releasate from bacterially-contaminated 
platelets on the activation status of primary human neutrophils, HL-60 neutrophils 
and U937 monocytes, by flow cytometric assessment of established activation 
markers (CD11b, CD54 and CD66b).  
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 Determine the effects of recombinant human RANTES (rhRANTES) on the activation 
status of primary human neutrophils, HL-60 neutrophils and U937 monocytes, by flow 
cytometric assessment of established activation markers (CD11b, CD54 and CD66b). 
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2.0 Methods  
 
2.1 Media and Bacterial Preparation 
All media used was prepared in accordance the manufacture’s guidance and sterilised using 
an autoclave at 121oC and 100 kPa for 20 min. The media was cooled in a water bath at 50oC 
for 30 min. Stock cultures of S. epidermidis DSM28319, S. marcescens NCTC9741, E. coli 
NCIMB10213 (wild-type/WT) and multi-resistant E. coli 82268 were streaked onto tryptone 
soy agar (TSA) (Oxoid, UK), stored in a chiller (4°C) and replaced every 4 weeks. A 10 mL 
volume of tryptone soy broth (TSB) (Oxoid, UK) was added to a sterile universal, and a single 
colony of S. epidermidis, S. marcescens, E. coli and multi-resistant E. coli was added and the 
culture was incubated for 24 h at 37oC. The culture was centrifuged at 1731 g for 10 min and 
the supernatant discarded. The cells were washed with 10 mL of sterile distilled water and 
centrifuged again. The supernatant was again discarded and the pellet resuspended with 10 
mL of sterile distilled water, vortexed and adjusted to an optical density (OD) of 1.0 ± 0.05 at 
540 nm using a spectrophotometer (Jenway 3605, UK); sterile distilled water was used as the 
blank. The cell concentration corresponded to approximately 1.00 x 109, 2.41 x 108, 1.3 x 109 
and 5.73 x 109 colony-forming units per mL (CFU mL) for S. epidermidis, S. marcesens, E. coli 
and multi-resistant E. coli respectively. This was calculated after performing serial dilutions 
and plate counts (n = 3). 
2.2 Zone of Inhibition (ZoI) Assay 
One hundred microliters of cell suspension were pipetted and spread evenly across 25 mL 
TSA plates. An antibiotic testing ring (Gram negative and Gram positive specific) (Mast Group 
Ltd., UK) was placed on the agar and incubated at 37oC for 24 h. The zones of inhibition were 
measured in mm and an average mean value was determined (n = 3). Antibiotic susceptibility 
was determined by comparing ZoIs to the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) Version 9.0 database.  
2.3 Cytometric Bead Array (CBA) 
 
2.3.1 CBA Standard Preparation 
The standards for CBA were prepared according to the manufacturer’s guidance. A vial of 
lyophilized standard from each BD CBA Human Soluble Protein Flex Set were pooled into one 
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15 mL falcon tube and was labelled as the ‘Top Standard’. The standards were reconstituted 
with 4 mL of Assay Diluent and was equilibrated for 15 min at room temperature then mixed 
with a pipette. A dilution of 1:2 of the standard was made by pipetting 500 µL of the top 
standard with 500 µL of the Assay Diluent and was thoroughly mixed with the pipette. Further 
dilutions were made to obtain 1:4, 1:8, 1:16, 1:128 and 1:1256 concentrations with the assay 
diluent as the blank. 
2.3.2 Capture Beads and PE Detection Reagent Preparation 
The capture beads stock vials for TNF-, IL-1β, IL-6, and RANTES were vortexed for 15 s to 
ensure thorough resuspension of the beads. Undiluted capture beads were provided so that 
1 L was used for one test. The volume required for each capture beak stock was scaled 
according to the number of tests run and the volume of capture bead diluent required was 
calculated as follows: 
Capture Bead Diluent (L) = (Number of Tests x 50 L) – (Number of Cytokines x Number of 
Tests)            [1] 
The capture beads were pipetted into a tube containing capture bead diluent labelled ‘Mixed 
Capture Beads’. The ‘Mixed PE Detection Reagent’ was prepared following the same 
procedure, using the PE detection reagent provided in each kit and the detection reagent 
diluent. The mixed PE detection reagent was then stored at 4oC and protected from light until 
ready for use.  
2.3.4 Performing the Human Soluble Protein Flex Set Assay 
A volume of 50 L of either a standard or a test sample was added to the appropriate tubes. 
The mixed capture beads were vortexed for 5 s and 50 L was added to all tubes and mixed 
with a pipette. The tubes were incubated at room temperature for 1 h. After this incubation, 
50 L of the mixed PE detection reagents were added to each tube, gently mixed with a 
pipette and incubated at room temperature for 2 h in the dark. After incubation, 1 mL of wash 
buffer was added to each tube, mixed and the tubes were centrifuged at 200 g for 5 min. The 
supernatant was carefully aspirated with a pipette and 300 L of wash buffer was added to 
each tube followed by a brief vortex to resuspend the beads. The BD Accuri C6F1 flow 
cytometer was set up with the 2 blue, 2 red instrument configuration and the FL3 laser filter 
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was changed to the 780/60 filter. The beads were run through a 2000 event limit in the R1 
gate at medium flow rate. The standards were run first, starting at the lowest concentration 
first, followed by the samples. The data was exported to FCAP Array software (Version 3.0) to 
be analysed.  
2.4 Cell Culture and HL-60 Differentiation 
U937 and HL-60 cells were cultured in RPMI-1640 media (Lonza, Belgium) supplemented with 
10% foetal bovine serum (Sigma-Aldrich, UK) and 2% penicillin streptomycin (Lonza, Slough, 
UK) and incubated at 5% CO2 for 24 h at 37oC. The media was changed every 72 h and cells 
were cultured at a concentration of 0.5 x 106 cell/mL. A ratio of 1:1 of cell suspension and 
trypan blue (Sigma-Aldrich, UK) were used to assess cell viability using a TC10 automated cell 
counter (BioRad, Singapore).  
 
A concentration of 0.5 x 106 cells/mL of HL-60 were differentiated into neutrophils with the 
addition of 1.3% dimethyl sulfoxide (DMSO) (Fisher). The cells were incubated for 48 h and 
72 h at 37oC and 5% CO2. Confirmation of HL-60 cells differentiation into neutrophils were 
assessed by measuring the expression of CD11b. Untreated differentiated HL-60 and U927 
cells were used as negative controls. PRP treated cells were used as positive controls for the 
protocols described in 2.7.3 and 2.7.4.  
 
2.5 Isolation of Human Primary Neutrophils   
Ethical approval for the use of primary human neutrophils was granted. Healthy adult 
volunteers gave written, informed consent to donate whole blood. Whole blood was 
collected in ethylenediaminetetraacetic acid (EDTA) coated vacutainers (BD Bioscience, New 
Jersey, USA). Lysing solution was made using 0.8% of ammonium chloride (Sigma-Aldrich, 
Dorset, UK) and 0.1 mM of EDTA (Sigma-Aldrich, Dorset, UK) in sterile distilled water buffered 
with potassium bicarbonate (Sigma-Aldrich, Dorset, UK) to a pH of 7.2 to 7.6. Neutrophils 
were isolated by adding lysing solution to whole blood in a 1:10 ratio and was gently mixed 
with a pipette and placed in ice for 10 min. The mixture was centrifuged for 5 min at 500 g 
with the supernatant discarded, and the cells were washed twice with 45 mL of Dulbecco’s 
Phosphate Buffered Saline (DPBS) (Lonza, Belgium). Cells were counted using the automated 
counter and ready for experimentation.   
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2.6 May-Grüwald Stain  
HL-60 promyelocytes, HL-60 DMSO-treated neutrophils and primary human neutrophils were 
visually confirmed through May-Grüwald stains (VWR, UK). A volume of 200 µL of neutrophils 
were taken and smeared onto glass slides using the cytospin (Sigma-Aldrich, UK) at 500 g for 
10 min. The samples were then fixed with methanol (Fisher Scientific, Leicestershire, UK) for 
5 min and dried at room temperature. The May-Grüwald stain was diluted at a ratio of 1:10 
with distilled water and samples were immersed with the diluted stain for 4 min. The stain 
was rinsed off by pouring distilled water and dried at room temperature in the class II airflow 
cabinet ready to be observed under the light microscope. 
 
2.7 Bacterial Contamination of Platelet-Rich-Plasma (PRP) 
 
2.7.1 Biofilm Growth  
Plasticized poly(vinyl chloride) (p-PVC) platelet bags (Terumo BCT, USA) were hole punched 
into coupons with a diameter of 11 mm. The p-PVC coupons were sterilised in 70% ethanol 
for 10 min and rinsed in distilled water and dried in the class II airflow cabinet. A sterilised p-
PVC coupon with the rough surface up, was placed in each well of a 12-well plate (Nunc Non-
Treated Multidishes, Thermo Fisher Scientific, UK) along with 1.8 mL of TSB. The coupons 
were pushed to the bottom of well using the reverse end of a sterile swab. The 12 well plate 
was left at room temperature overnight on the bench to determine if the coupons were fully 
sterile and to identify any contaminant growth present. An overnight culture of the test 
microorganism was prepared and diluted to obtain a concentration of 1.0 x 108 CFU mL. A 
bacterial suspension of 200 L was added to the appropriate wells to give a working 
concentration of 1.0 x 107 CFU mL. The 12 well plate was parafilmed to prevent the media 
from evaporating. The plates were incubated at 22oC for 7 days with gentle shaking (68 rpm). 
Following incubation, all the media in each well was removed via pipetting, leaving the 
coupons and biofilm behind. The wells were all washed with 2 mL of Tyrode’s buffer, carefully 
at the side of the well to not disturb the biofilm and the plate was gently shaken manually for 
5 s. The buffer was pipetted out to remove any unbound planktonic cells. The 12 well plates 
and coupons were air dried in a class II cabinet for 1 h.  
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2.7.2 PRP Isolation 
A volume of 20 mL of whole blood from healthy volunteers was collected into 3.2% sodium 
citrate vacutainers (BD Biosciences, New Jersey, USA). The vacutainers were centrifuged at 
180 g for 20 min to compact the red blood cells to the bottom of the tube whilst the PRP was 
left as the supernatant. The PRP was pipetted out without disturbing the compacted red 
blood cells into sterile 50 mL falcon tubes.  
 
Note: The total volume of PRP obtained will vary from donor to donor, as this is dependent on 
their haematocrit. 
 
2.7.3 PRP Treatment of Biofilms 
The PRP was diluted with Tyrode’s buffer in a ratio of 1:1 in 50 mL falcon tubes prior to being 
added to the biofilms. Two millilitres of diluted PRP were added to each well. These were 
incubated at 22oC for 4 h with gentle agitation (68 rpm) prior to experimental work. Following 
incubation, the bacterial contaminated PRP was removed from the wells and placed in sterile 
15 mL falcon tubes. They were spun down at 1200 g for 10 min and the resultant supernatant 
was pipetted into sterile 15 mL falcon tubes to remove the platelets. The supernatant was 
centrifuged at 1721 g for 5 min to remove the remaining bacteria from the sample. A hundred 
microliters of platelet and bacteria free supernatant was added to the appropriate wells of a 
96 well plate (Sarstedt, Germany) containing 100 L of U937 cells or HL-60 neutrophils. The 
96 well plate was incubated at 37oC, 5% CO2 for 24 h for flow cytometry.  
 
Note: Experiments with S. marcescens were discontinued as the production of coagulase 
interfered with the experiments. 
  
2.7.4 PRP Treatment of Planktonic Bacteria 
An overnight culture of S. epidermidis, E. coli and multi-resistant E. coli was made up to a 
concentration of 2 x 107 CFU mL with Tyrode’s buffer. The culture was diluted to 1 x 107 
following the addition of PRP at a ratio of 1:1 in sterile eppendorf tubes. The samples were 
incubated at 22oC for 4 h with gentle agitation (68 rpm) prior to flow cytometric analysis.   
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2.8 Recombinant RANTES Treatment 
A stock solution of RANTES was prepared by mixing 200 µL of sterile DPBS and 20 µg of 
RANTES powder (Pepro Tech, UK).  Working solution ‘A’ was made using a 1 in 100 dilution of 
the stock solution and sterile RPMI-1640 media i.e. 2 µL of RANTES stock solution to 198 µL 
RPMI-1640 media with the final concentration of working solution ‘A’ as 1 µg/mL. The working 
solution ‘A’ was diluted by 1 in 50 to achieve a final concentration of 20 ng/mL, further 
dilutions was made to obtain concentrations of 2 ng/mL, 0.2 ng/ 4 mL, 0.02 ng/mL and 0.002 
ng/mL. A hundred microliters of the appropriate concentrations were added to wells 
containing 100 µL of either U977 monocytes, HL-60 neutrophils or human primary neutrophils 
in a 96 well plate. The 96 well plate was incubated at 37oC, 5% CO2 for 24 h before flow 
cytometry.  
 
2.9 Flow Cytometry  
After incubation, the cells were transferred into 1.5 mL eppendorf tubes and centrifuged for 
5 min at 500 g with the supernatant discarded. The cells were washed with 500 µL of RPMI-
1640 media and centrifuged again. The supernatant was removed and the cell pellet was re-
suspended with 200 µL of paraformaldehyde (Sigma-Aldrich, UK) and was left to incubate for 
10 min at room temperature. This was followed by an addition of 200 µL of DPBS and was 
centrifuged immediately. The number of samples that were required to be stained with anti-
CD11b, anti-54 and anti-66b (BD Pharmingen, USA) was determined and the antibodies were 
diluted in a 1:20 ratio with washing buffer (10% FBS in DPBS). A volume of 50 µL of the 
antibody mixture was added to the appropriate samples and was incubated in the fridge in 
the dark for 30 min. The samples were washed with 200 µL of washing buffer and was 
centrifuged at 500 g for 5 min. The supernatant was removed and the samples were re-
suspended with 500 µL DPBS. CD54, CD11b and CD66b expression was assessed through 
10,000 events (live cells) using flow cytometer with the BD Accuri C6 software (Biosciences, 
USA) after gating in the forward scatter/side scatter and fluorescence parameter 1, 2 and 4 
(FL1, FL2, FL4) windows. Data was presented as average percentage CD54+, CD11b+ and 
CD66b+ cells (%) and median fluorescence intensity (MFI) relative to unstained U937, HL-60 
neutrophils and primary human neutrophils from three independent experiments.  
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2.10 Statistical Analysis  
All statistical analysis was performed in GraphPad Prism version 7.00. Results were presented 
with standard error of the mean (SEM) as error bars on graphs. As data One-Way ANOVA and 
Tukey post-hoc test was used to compare significance between mean values at 95% 
confidence.  
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3.0 Results 
 
3.1 Zones of Inhibition of Transfusion-Associated Sepsis/Transfusion-Associated Bacterial 
Infection Relevant Bacteria  
Zones of inhibition (ZoI) assays were carried out to determine the antibiotic resistance of the 
four pathogens relevant to transfusion-associated sepsis/transfusion-associated bacterial 
infection (T-AS/T-ABI) used in this work, which are S. epidermidis, S. marcescens, E. coli and 
multi-resistant E. coli.  
 
Multi-resistant E. coli displayed the greatest antibiotic resistance (hence its name) with 
resistance found in 5 out of 8 antibiotics tested (ampicillin, kanamycin, nalidixic acid, 
nitrofurantoin and tetracycline) (Fig. 3). Chloramphenicol appears to be the only antibiotic to 
have antimicrobial activity to multi-resistant E. coli with a ZoI of 20 mm. The EUCAST 
breakpoints for colistin sulphate, kanamycin and streptomycin have not been previously 
established therefore the sensitivity of E. coli and multi-resistant E. coli to these antibiotics 
cannot be determined. However, multi-resistant E. coli appear to be weakly susceptible to 
both antibiotics.  
 
S. marcescens had the second greatest antimicrobial resistance as no zones were observed 
for ampicillin, colistin sulphate, nitrofurantoin and streptomycin (Fig. 4). According to EUCAST, 
chloramphenicol is the only antibiotic with antimicrobial activity against S. marcescens. Data 
for nalidixic acid, and tetracycline was not found on the EUCAST database for 
Enterobacterales therefore, no comments can be made on their antimicrobial activity. 
 
S. epidermidis showed intermediate antibiotic susceptibility out of the four pathogens tested 
in which susceptibility was found for chloramphenicol, fusidic acid and tetracycline. S. 
epidermidis was the most sensitive to fusidic acid with an average ZoI of 29.5 mm followed 
by tetracycline (28.3 mm) and chloramphenicol (19.7 mm) (Fig. 5). Resistance for S. 
epidermidis was found for erythromycin, penicillin G, streptomycin and tetramycin as no 
zones were observed. According to the European Committee on Antibiotic Susceptibility 
Testing (EUCAST), most Staphylococcus spp. are resistant to penicillin class antibiotics through 
the production of penicillinase therefore, it is assumed that S. epidermidis is resistant to 
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oxacillin even though a zone of 14.7 mm was observed. Data on the susceptibility of S. 
epidermidis for novobiocin was not found on the EUCAST database therefore, no comments 
on its antimicrobial activity could be made.  
 
The pathogen that showed the highest antibiotic susceptibility was E. coli. Sensitivity was 
found in ampicillin, chloramphenicol, nitrofurantoin and tetracycline in accordance to 
EUCAST breakpoints. Tetracycline showed the highest activity against E. coli with a zone of 31 
mm followed by chloramphenicol (26.7 mm), nitrofurantoin (20.7 mm) and ampicillin (19.5 
mm). Nalidixic acid was the only antibiotic observed to have no antimicrobial effect on E. coli 
indicating its resistance (Fig. 3).  
 
 
 
Figure 3. Zones of inhibition of the Gram-negative E. coli and multi-resistant E. coli. Data are 
presented as Mean ± SEM, where n = 3. Resistance for E. coli was only found with nalidixic 
acid while multi-resistant E. coli was found to be resistant to ampicillin, kanamycin, nalidixic 
acid, nitrofurantoin and tetracycline. 
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Figure 4. Zones of inhibition of Gram-negative S. marcescens showing the second greatest 
antimicrobial resistance between all bacteria tested. Data is presented as Mean ± SEM, where 
n = 3. 
 
Figure 5. Zones of inhibition of the Gram-positive S. epidermidis. Data is presented as Mean 
± SEM, where n = 3. Fusidic acid was the most effective antibiotic whilst erythromycin, 
penicillin G and streptomycin demonstrated no antimicrobial effect on S. epidermidis. 
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3.2. Analysis of bacterially-contaminated platelet releasates 
Platelet-rich plasma (PRP) from healthy participants was contaminated with two key bacterial 
species frequently implicated in T-ABI/T-AS, namely S. epidermidis and S. marcescens. The 
PRP samples were exposed to the bacteria in both planktonic and biofilm forms for four and 
twenty-four hours, and supernatants (free from bacteria and platelets) were collected for 
analysis of major cytokines/chemokines (IL-1β, IL-6, TNF-α and RANTES) by Cytometric Bead 
Array. Standard curves (Fig. 6) of the four cytokines tested were constructed to allow for 
quantification of the relevant cytokine/chemokine in the test samples.  
 
 
 
A 
 
B 
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Figure 6. Standard curves of the four cytokines tested: A) Human TNF-α, B) Human IL-6, C) 
Human IL-1β and D) Human RANTES. MFI = mean fluorescent intensity, concentration is 
measured in pg/mL. Data is presented as 10,000 data points per individual reads. 
 
Levels of IL-1β, IL-6, and TNF-α were not significantly altered by incubation with S. epidermidis 
or S. marcescens in either planktonic or biofilm forms, and in fact, the levels of these cytokines 
in the platelet supernatant were negligible. However, the level of RANTES was significantly 
increased (Fig. 7 – Fig. 10) in comparison to the concentrations of IL-1β, IL-6, and TNF-α for 
both planktonic and biofilm forms of S. epidermidis and S. marcescens. Overall, the planktonic 
forms of both species incubated with PRP for 4 h did not elicit any concentrations of IL-1β, IL-
6, and TNF-α. There is a general trend of increased cytokine production when PRP had been 
treated with a higher concentration (1 x 108 CFU/mL) of planktonic S. epidermidis and S. 
C 
D 
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marcescens for 24 h with the exception of RANTES with S. epidermidis and IL-1 with S. 
marcescens. The same trend can also be seen when PRP was incubated with more mature 
biofilms (established over 7 days compared to 5 days) of S. epidermidis and S. marcescens for 
24 h in which bacterial counts were higher. RANTES appeared to be constitutively secreted 
within the plasma by platelets as its concentration was measured at 7598.65 pg/mL and 38, 
224.51 pg/mL for the controls for the planktonic form of S. epidermidis and S. marcescens 
incubated at 4 h and 24 h respectively. These concentrations are far greater than the 
concentrations obtained for IL-1β, IL-6, and TNF-α where the concentration was found to be 
0 pg/mL. The cytokine/chemokine response does not appear to be dependent on the 
contaminating bacterial species. 
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Figure 7. Concentrations of human TNF-α planktonic and biofilm forms of A) S. epidermidis 
and B) S. marcescens. Data are presented as 10,000 data points acquired per individual read. 
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Figure 8. Concentrations of human IL-6 planktonic and biofilm forms of A) S. epidermidis and 
B) S. marcescens. Data are presented as 10,000 data points acquired per individual read. 
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Figure 9. Concentrations of human IL-1β planktonic and biofilm forms of A) S. epidermidis and 
B) S. marcescens. Data are presented as 10,000 data points acquired per individual read. 
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Figure 10. Concentrations of human RANTES planktonic and biofilm forms of A) S. epidermidis 
and B) S. marcescens. Data are presented as 10,000 data points acquired per individual read.  
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3.3 Preparation of leucocyte populations for testing the effects of bacterially contaminated 
platelet releasates on immune responses. 
The transformed cell lines U937 and HL-60 represent monocytes and promyelocytes 
respectively, and the bacterially-contaminated platelet releasate can be applied directly to 
these cells to determine the effects on monocytes and promyelocytes (immature myeloid 
cells). However, in order to test such effects on neutrophils, the HL-60 cells must be 
stimulated to differentiate down the neutrophil differentiation pathway. Low concentrations 
(1.3%) of DMSO during 72 h culture have been reported to induce such differentiation (Rincón 
et al., 2018).  
 
The differentiation of HL-60 cells into neutrophils after treatment with 1.3% DMSO was 
confirmed via May-Grüwald staining and increased expression of the marker CD11b using 
flow cytometry (Fig. 16 and Fig. 17 respectively).    
 
The incubation of DMSO with HL-60 cells at time points 24 h, 48 h, 72 h, 96 h and 120 h 
induced morphological changes that were similar to those found in primary neutrophils such 
as segmented nuclei, chromatin condensation and decreased nucleocytoplasmic ratio (Fig. 
15). The segmentation of the nuclei was most prominent at 72 h. Post-72 h with DMSO, the 
cells began to show prominent signs of apoptosis. 
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Figure 11. May-Grünwald stained cytosmears of HL-60 cell line. A) Control – HL-60 not treated 
with DMSO. B) 24 h treatment with DMSO. C) 48 h treatment with DMSO. D) 72 h treatment 
with DMSO; arrows indicate the segmented nuclei that is characteristic of neutrophils. E) 96 
h treatment with DMSO. F) 120 h treatment with DMSO. 
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DMSO-treated HL-60 were stained with anti-CD11b as CD11b is an early differentiation 
marker for neutrophils (Drayson et al., 2001). Flow cytometric analysis of CD11b expression 
was shown to increase when HL-60 cells were treated with DMSO for both time points tested 
(48 h and 72 h) (Fig. 12 A and B respectively). Statistical analysis showed there was significance 
(p < 0.05) between the control and 48 h DMSO treated HL-60 cells but no significance (p > 
0.05) was found for the 72 h DMSO treated HL-60 cells. It must be noted that although no 
statistical significance is found for the 72 h DMSO treated HL-60, CD11b expression was 
increased in comparison to the control and untreated HL-60. 
 
 
 
 
Figure 12. CD11b expression of HL-60 cells treated with DMSO for A) 48 h and B) 72 h. 
Significance was found between the control and DMSO treated HL-60 in terms of CD11b 
expression (p < 0.05), *p = 0.0304 for 48 h. No significance was found in terms of CD11b 
expression (p > 0.05) for 72 h.  Data are presented as Mean ± SEM, where n = 3. 
 
 
 
 
 
 
A 
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Primary human neutrophils obtained from healthy donors were also used in this work as a 
comparison for the HL-60 neutrophils. To confirm that a population of primary human 
neutrophils were isolated from the healthy donors, samples were stained with May-Grüwald 
and showed definitive lobed nuclei indicating that the neutrophils were mature (Fig. 13).  
 
 
A 
 
 
 
B 
 
C 
 
D 
 
Figure 13. May-Grüwald staining of primary human neutrophils obtained by whole blood 
lysing of EDTA-anticoagulated blood from a healthy donor nuclei indicating that the 
neutrophils were mature.  
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3.4 Effect of bacterially-contaminated platelet releasates on leucocyte surface activation 
markers. 
To determine the effects of the bacterially-contaminated platelet-releasates on leucocyte 
subsets, transformed cell lines (U937 monocytic cell line, HL-60 promyelocytic cell line, and 
HL-60-derived neutrophils) as well as primary leucocytes were used. Surface activation 
markers CD11b, CD54 and CD66b were analysed by flow cytometry. CD66b was not analysed 
in U937 monocytes as the marker is neutrophil-specific (Lakschevitz et al., 2016).  
 
It must be noted when both cell lines were treated with the biofilm-contaminated platelet-
releasates coagulation had occurred despite the pathogens tested being coagulase-negative; 
which may have affected the results of this study.  
 
3.4.1 Effect of bacterially-contaminated platelet releasates on U937 monocyte surface 
activation markers. 
U937 monocytes was treated with platelet releasates from PRP incubated with S. epidermidis, 
E. coli and multi-resistant E. coli in planktonic and biofilm forms. No statistical differences 
were seen in both CD54 and CD11b expression (p > 0.05) when U937 monocytes were 
incubated with releasate from planktonic S. epidermidis-contaminated PRP (Fig. 14 A and B).  
CD11b appeared to be slightly down regulated when U937 cells were treated with releasate 
from planktonic S. epidermidis-contaminated PRP. This would indicate that platelets primed 
by S. epidermidis did not affect the activation status of U937 monocytes. 
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Statistical significance was not found when comparing expression of CD54 or CD11b between 
untreated cells and those exposed to E. coli-treated platelet releasate (Fig. 15 A and B), again 
indicating that E. coli-primed platelets do not have an effect on the activation status of U937 
monocytes. 
 
 
Figure 14. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releaseate collected from platelets contaminated with planktonic S. epidermidis for 24 h. 
Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis 
was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. 
Significance was not found for CD54 and CD11b expression (p > 0.05). 
A B 
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In contrast to these results, incubation of planktonic multi-resistant E. coli induced a highly 
significant upregulation of CD54 in U937 monocytes with p values of less than 0.0001 when 
compared to the control and plasma treatment group (Fig. 16 A). As planktonic S. epidermidis 
and WT E. coli contaminated platelet releasates had no effect on U937 monocyte CD54 
expression, it can be interpreted that the multi-resistant strain was more effective in inducing 
expression of CD54 and therefore activating monocytes more strongly than S. epidermidis and 
the non-resistant E. coli strain. Although no statistical difference can be found when analysing 
the CD11b data (Fig. 16 B), a different trend can be seen with multi-resistant E. coli compared 
to S. epidermidis and non-resistant E. coli, in which CD11b activation increased rather than 
decreased as seen in the other two pathogens.   
 
 
 
 
 
Figure 15. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releaseate collected from platelets contaminated with planktonic E. coli for 24 h. Data are 
presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was 
performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance 
was not found for CD54 and CD11b expression (p > 0.05). 
A B 
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No changes in CD54 expression was observed following the treatment of platelets with 
planktonic S. epidermidis (Fig. 14). However, with the biofilm S. epidermidis platelet releasate, 
a minor decrease in CD54 expression was demonstrated (p = 0.0209) (Fig. 17 A). In contrast, 
CD11b expression appeared to be increased when U937 monocytes were treated with this 
same platelet releasate, but no statistical significance was observed (p > 0.05) (Fig. 17 B). 
Taken together, the results may suggest that planktonic and biofilm forms of pathogens 
induced different cytokine profiles via alternative mechanisms leading to contrasting results 
in surface marker expressions on leucocytes.  
 
 
 
Figure 16. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releaseate collected from platelets contaminated with planktonic multi-resistant E. coli for 
24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical 
analysis was performed using one-way ANOVA. Statistical significance was defined as p < 
0.05. Significance was found for CD54 expression in which ****p = < 0.0001 while CD11b 
expression had no statistical significance (p > 0.05). 
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The expression of CD54 was upregulated when U937 monocytes were incubated with 
releasate from E. coli biofilm-contaminated PRP when compared to the control and plasma 
treatments however, no statistical significance could be seen (Fig. 18 A). On the other hand, 
CD11b expression was significantly upregulated following treatment of the monocytes with 
releasate from E. coli biofilm-contaminated PRP (p = 0.0025) (Fig. 18 B). However, the CD11b 
expression on monocytes treated with platelet releasate that had not been in contact with 
bacteria (plasma) was also significantly elevated in comparison with control samples (p = 
0.0004), and the levels were not different from those following treatment with bacterially-
primed platelets. This indicates that something in the plasma was causing the upregulation of 
CD54 and not the pathogen itself.  
 
 
 
Figure 17. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releaseate collected from platelets contaminated with S. epidermidis biofilm for 24 h. Data 
are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was 
performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance 
was for CD54 *p = 0.0209, but no significance was found for CD11b expression (p > 0.05). 
A B 
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CD54 surface expression was found to be highly upregulated (p < 0.001) in response to 
treatment of monocytes with releasate from platelets contaminated with the biofilm form of 
multi-resistant E. coli (Fig. 19 A). Although this was also the case for CD11b expression, this 
transmembrane protein was also found to be upregulated in response to platelet releasate 
that had not been contaminated with bacterial biofilm (Fig. 19 B). Overall, the planktonic and 
biofilm form of multi-resistant E. coli displayed the same trend, with the exception of the 
plasma treatment in the planktonic form, where both surface markers were increased.  
 
 
 
Figure 18. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releaseate collected from platelets contaminated with E. coli biofilm for 24 h. Data are 
presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was 
performed using one-way ANOVA. Statistical significance was defined as p < 0.05. No 
statistical significance for CD54 expression (p > 0.05) while significance was found for CD11b 
expression, ***p = 0.0004, **p = 0.0025. 
A B 
 48 
 
3.2.2 Effect of bacterially-contaminated platelet releasates on HL-60 neutrophils cell 
surface activation markers. 
The expression of CD54, CD11b and CD66b were measured on HL-60 neutrophils via flow 
cytometry following stimulation with various platelet releasates to compare whether surface 
expression were similar or different to those observed with U937 monocytes. Statistical 
significance were seen with CD54 and CD66b but not CD11b (p > 0.05) with planktonic S. 
epidermidis (Fig. 20). All the surface markers tested appeared to increase after incubation 
with planktonic S. epidermidis suggesting that the platelets primed with the pathogen had an 
effect on HL-60 neutrophil activation status.  
Figure 19. A) CD54 and B) CD11b expression of U937 cells treated, or not, with platelet 
releasate collected from platelets contaminated with multi-resistant E. coli biofilm for 24 h. 
Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis 
was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. 
Statistical significance was found for CD54 expression with **p values of 0.0023 (control vs 
multi-resistant E. coli) and 0.007 (plasma vs multi-resistant E. coli). CD11b expression was 
found to be statistically significant, *p = 0.014 and **p = 0.0016. 
A B 
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Figure 20. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with planktonic S. epidermidis for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical 
analysis was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance was found for CD54 expression on 
HL-60 cells between all three treatment groups, *p = 0.129, ***p = 0.0003 and ****p = <0.0001. No significance was found for CD11b expression 
(p > 0.05). Significance was only found between the control and planktonic S. epidermidis treatments for CD66b, *p = 0.018. 
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Expression of CD54 and CD11b was increased after treatment of planktonic WT E. coli 
contaminated PRP while no changes in CD66b expression were observed (p > 0.05) (Fig. 21 C). 
As a significant difference can be seen between the control and the plasma (p = 0.0009) it is 
implicated that the upregulation of CD54 was caused by the factors released by the platelets 
prior to priming or from factors that were already present in the plasma (Fig. 21 A). A 
significant difference was also found between the plasma and planktonic WT E. coli (p = 0.195). 
This suggests that the platelet releasate primed with planktonic E. coli has a greater effect on 
upregulating CD54 than with plasma alone. Significant differences can be found between the 
control and planktonic WT E. coli contaminated PRP (**p = 0.0012), and the plasma and 
planktonic WT E. coli contaminated PRP samples (**p = 0.003) for the expression of CD11b 
(Fig. 21 B). As no significance difference was found between the control and plasma 
treatments in reference to CD11b, it may be suggested that platelets primed with planktonic 
E. coli contaminated releasate has an effect on the activation status of HL-60 neutrophils.   
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Figure 21. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with planktonic E. coli for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was 
performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance was found for CD54 expression on HL-60 cells 
between all three treatment groups, *p = 0.195, ***p = 0.0009 and ****p = < 0.0001. Significance was also found for CD11b, **p = 0.0012 for 
control and E. coli, **p = 0.003 for plasma and E. coli. Significance was not found for CD66b (p > 0.05). 
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CD54 was significantly upregulated when HL-60 neutrophils were treated with multi-resistant 
E. coli contaminated PRP (Fig. 22 A) compared to all the other bacteria, surface markers and 
cell lines tested. As no significance was detected between the control and plasma treatment 
on CD54 expression, it may be suggested that upregulation of CD54 was mainly caused by 
platelet releasate contaminated with planktonic multi-resistant E. coli. A slight increase in 
CD11b expression was observed but this was not significant (p > 0.05) (Fig. 22 B). CD66b 
expression was also upregulated after treatment. However, expression of CD66b was not as 
high as that of CD54 (Fig. 22 C).  
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Figure 22. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with planktonic multi-resistant E. coli for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  
Statistical analysis was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance was found for CD54 
expression on HL-60 cells ****p = < 0.0001. No significance for CD11b (p > 0.05). Significance was found for CD66b **p = 0.0063, ***p = 0.0004. 
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HL-60 neutrophil CD54 expression was found to increase when the cells were treated biofilm-
contaminated platelet releasates for S. epidermidis, E. coli and multi-resistant E. coli biofilms 
respectively (Fig. 23 A, Fig. 24 A and Fig. 25 A). However, in the case of the S. epidermidis, 
there was no significant difference in the CD54 expression between neutrophils treated with 
platelet releasates that had not been in contact with bacteria, and those that had, indicating 
that the small observed increase in expression is due to components within the blood plasma 
that are independent of bacterial contamination. In contrast to this E. coli (WT or multi-drug 
resistant) appeared to have a significant effect on neutrophil activation status with multi-drug 
resistant E. coli having the biggest effect. CD11b and CD66b expression did not appear to be 
affected by incubation with S. epidermidis biofilm contaminated platelet relesates, as 
significant differences were not observed between these samples and those treated with 
non-contaminated platelet releasates (Fig. 23 B and C). 
 
CD11b and CD66b expression of HL-60 cells treated with WT E. coli biofilm were weakly 
upregulated (Fig. 24 B and C). Statistical significance was not found between the plasma and 
biofilm treatment for both surface markers therefore the increased expression observed is 
likely to be caused by plasma components rather than the bacterial priming of platelets.  
 
Similarly, to the WT E. coli biofilm treatment, expression of CD11b was increased to an extent 
of the multi-resistant E. coli biofilm contaminated PRP treatment when compared to the 
control therefore, the same can be said about plasma components are causing these changes 
(Fig. 25 B). As for CD66b expression, it was upregulated when HL-60 neutrophils were treated 
with plasma however, expression was downregulated when treated with biofilm 
contaminated platelet releasate (Fig. 25 C). Although no significance was found for the biofilm 
treatment, the multi-resistant E. coli may have an antagonistic effect on platelets or an 
antagonistic effect on plasma factors. 
 
Overall, multi-resistant E. coli had the most significant effect on the upregulation of CD54 in 
comparison to S. epidermidis and WT E. coli in both planktonic and biofilm forms. CD11b and 
CD66b expression was either moderately increased or not changed for all three pathogens in 
both planktonic and biofilm forms.  
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Figure 23. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with S. epidermidis biofilm for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis 
was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance was found for CD54 expression on HL-60 cells 
only with control vs. plasma **p = 0.0014 and control vs. biofilm ***p = 0.0002. No significance was found for CD11b and CD66b expression (p 
> 0.05). 
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Figure 24. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with E. coli biofilm for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was 
performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Significance was observed for CD54, *p = 0.282 and ***p = 
0.0006. Significance was only found between the control and E. coli biofilm for CD11b and CD66b, *p = 0.0249 and *p = 0.423 respectively. 
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Figure 25. A) CD54, B) CD11b and C) CD66b expression of HL-60 cells treated, or not, with platelet releaseate collected from platelets 
contaminated with multi-resistant E. coli biofilm for 24 h. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical 
analysis was performed using one-way ANOVA. Statistical significance was defined as p < 0.05. Stastical significance was observed for CD54, 
****p = < 0.0001, CD11b *p = 0.0360 and CD66b *p = 0.0309. 
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3.5 Effect of recombinant human RANTES (rhRANTES) on leucocyte surface activation 
markers.  
As RANTES was found to be the most significant chemokine within the bacterially 
contaminated platelet releasates (Fig. 10), the effect of recombinant human RANTES 
(rhRANTES) on the activation status of these leucocyte subtypes was evaluated.  
 
3.5.1 Effect of rhRANTES on U937 surface activation markers.  
For U937 cells, no significant difference was found (p > 0.05) between the expression of both 
CD54 and CD11b markers when U937 cells were incubated for 24 h with recombinant RANTES 
at varying concentrations (Fig. 26).  
 
 
  
A B 
Figure 26. A) CD54 and B) CD11b expression on U937 cells after 24 h treatment with 
rhRANTES. Data are presented as Mean ± SEM, where n = 3 for each treatment group.  
Statistical analysis was performed using one-way ANOVA with Tukey post-hoc tests. Statistical 
significance was defined as p < 0.05. No significance was found for either surface markers (p 
> 0.05). 
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3.5.2 Effect of rhRANTES on HL-60 Neutrophils Surface Activation Markers.  
The incubation of rhRANTES and HL-60 neutrophils appeared to have no effect on surface 
marker expression for CD54 and CD66b (Fig. 27 A and C respectively). A trend can be seen 
with CD11b in which the marker was down regulated as the concentration of rhRANTES 
increased (0.001 ng/mL and 0.01 ng/mL) (Fig. 27 B). CD11b expression peaked at 0.1 ng/mL 
and gradually decreased again as concentration increased. No statistical significance was 
found for all three surface markers.
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Figure 27. A) CD554, B) CD11b and C) CD66b expression on HL-60 differentiated neutrophils after 24 h incubation with rhRANTES. Data are 
presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was performed using one-way ANOVA with Tukey post-
hoc tests. Statistical significance was defined as p < 0.05. No significance was found for all surface markers at all concentrations of rhRANTES 
tested (p > 0.05).  
 61 
3.5.3 Effect of rhRANTES on primary human neutrophils. 
Treatment of rhRANTES with primary human neutrophils had variable effects on surface 
marker expression at different concentrations. However, no trend was observed with the 
exception of CD66b in which expression appeared to gradually decrease as the concentration 
of rhRANTES increased (Fig. 28 C). No statistical significance was found for CD54 expression 
and although expression peaked at 0.001 ng/mL it may be an anomaly (Fig. 28 A).  Significance 
for CD11b expression was only found at 0.1 ng/mL in which CD11b levels were downregulated 
(Fig. 28 B). CD66b expression declined as concentration of rhRANTES increased and 
significance was found for all concentrations with the exception of 0.001 ng/mL (Fig. 28 C).  
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Figure 28. A) CD54, B) CD11b and C) CD66b expression on primary human neutrophils after treatment of recombinant RANTES for 24 h. Data are 
presented as Mean ± SEM, where n = 3 for each treatment group.  Statistical analysis was performed using one-way ANOVA with Tukey post-hoc 
tests. Statistical significance was defined as p < 0.05. No significance was found for CD54. Significance was found for CD11b expression, *p = 
0.0247. Significance was found for CD66b expression, 0.01 ng/mL *p = 0.0303, 0.1 ng/mL **p = 0.0086, 1.0 ng/mL *p = 0.0231, 10 ng/mL **p = 
0.0033.   
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In summary, planktonic and biofilm forms of S. epidermidis had minimal to no effect on the 
activation status of U937 cells. Multi-resistant E. coli was the most potent pathogen to 
upregulate surface marker expression in U937 cells, WT E. coli on the other hand, showed the 
same effects as S. epidermidis in its planktonic form but does appear to potentially supress 
CD11b expression in its biofilm morphology. As for Hl-60 cells, all pathogens were capable to 
exert changes in surface marker expression (mainly CD54) in both planktonic and biofilm 
forms, with the biofilms appearing to be more effective in upregulating CD54. The variable 
activation status of both cell lines towards bacterially primed platelet releasate could be 
indicative of a differential platelet response to different bacteria, which in-turn resulted in a 
differential response by elements of the innate immune system. In general, treatment of 
rhRANTES on both cell lines and human neutrophils did not show any notable changes in the 
surface markers tested with the exception of CD66b on human neutrophils where increasing 
the concentration of rhRANTES decreases the levels of CD66b.   
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4.0 Discussion 
Blood products undergo strict regulations during collection and processing to ensure the 
quality of the product is maintained throughout its shelf-life with the overall aim of 
preventing the occurrence of adverse transfusion reactions. Implementation of risk reduction 
strategies and surveillance systems, more notably bacterial detection technologies and active 
surveillance, has reduced the number of reported incidences of transfusion reactions (Hong 
et al., 2016). However, episodes of T-AS remains as one of the greatest concerns of 
transfusion medicine, particularly since many immunocompromised patients that receive 
platelet products which are the most susceptible blood component to bacterial 
contamination. Despite the universal testing systems (BacT/ALERT®) in place to detect 
bacterial contamination in platelet units, false negatives sometimes occur, mainly due to the 
presence of slow-growing species that fail to produce the required level of CO2 required for 
detection (Benjamin and Wagner, 2007). 
 
However, the question remains as to how the bacterial species or their products interact with 
components of the recipient’s immune system following transfusion of the contaminated unit.  
The approach to this problem, presented in this thesis, was to determine the platelet 
secretory response to bacterial species commonly-implicated in T-AS, and investigate the 
effect of this platelet releasate on neutrophils and monocytes (the primary cells involved in 
the initial stages of sepsis). 
 
4.1 Zones of Inhibition of Relevant T-AS Bacteria 
It was important to firstly fully characterise the antibiotic susceptibility of the relevant T-AS 
bacteria being used in the study. S. epidermidis is considered one of the most clinically 
significant coagulase-negative Staphylococci as it is one of the most commonly isolated 
nosocomial pathogens (Eladli et al., 2019). Therefore, it would not be unexpected to find 
resistance to multiple antibiotics, as S. epidermidis is part of the natural skin flora and 
resistant strains may be selected during antibiotic therapy (Eladii et al., 2019). The results 
demonstrated, S. epidermidis was resistant to macrolides (erythromycin and streptomycin) 
which is encoded by the erm(C) gene (Sjӧlund et al., 2005). The product of the erm(C) gene is 
a methylase that acts on the adenine residue on the 23S RNA, resulting in a conformational 
change in the 50S ribosomal subunit and thus macrolides can no longer bind to its specific 
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site (Sjӧlund et al., 2005; Juda et al., 2016). It has been frequently reported that 
Staphylococcus spp. were resistant to penicillin conferred through the production of β-
lactamase (Baldwin et al., 1969) which may explain the absence of a zone of inhibition with 
penicillin G. In addition, a study reported over 70% of S. epidermidis strains were resistant to 
methicillin classed drugs (oxacillin). This may occur since methicillins share a similar structure 
to penicillins which β-lactamase could also act upon (Farrell et al., 2011). An implication of 
the antibiotic susceptibility profile for this strain of S. epidermidis would be that patients 
should be administrated with fusidic acid, tetracycline or chloramphenicol if found, to have 
been transfused with a S. epidermidis-positive platelet unit. Although data for the 
susceptibility of S. epidermidis to novobiocin was not found it is commonly used to distinguish 
it from Serratia saprophyticus (Eladli et al., 2019). 
 
S. marcescens has been recently recognised as a nosocomial pathogen after it was thought to 
be non-pathogenic to humans (Ramírez-Acros et al., 2006). Like E. coli, S. marcescens is 
abundant in the environment which provides plenty of opportunity for it to gain antimicrobial 
resistance through horizontal gene transfer. For example, aminoglycoside (e.g. kanamycin) 
resistance is conferred through the transfer of the acquisition of a plasmid coding for a 16S 
rRNA methylase from Pseudomonas aeruginosa (Doi et al., 2004). The susceptibility of the S. 
marcescens strain used in the study to kanamycin however, cannot be commented as the 
breakpoint was not available on EUCAST. Chloramphenicol would be the best antibiotic to use 
against infection with this specific strain of S. marcescens.  
 
As a highly versatile bacterium, being able to survive within the gastrointestinal tract of its 
host and the outside environment, E. coli will exhibit a variety of antibiotic susceptibility 
profiles. E. coli WT was highly susceptive to a wide range of antibiotics tested with the 
exception of nalidixic acid, indicating that this strain did not possess a wide range of antibiotic 
resistant mechanisms. Therefore, treatment with this particular strain can be easily 
accomplished using tetracycline, chloramphenicol, nitrofurantoin or ampicillin. Nalidixic acid 
is a quinolone-classed antibiotic that targets DNA gyrase and topoisomerase IV, both of which 
are essential for DNA, RNA and protein synthesis respectively (Sáenz et al., 2003). At low 
concentrations, nalidixic acid is bacteriostatic whilst high concentrations of the drug are 
bactericidal (Greenwood and O’Grady, 1978). Resistance to nalidixic acid could be conferred 
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through mutations of the gyrA and gyrB genes for DNA gyrase or mutations in the parC and 
parE genes for typoisomerase IV (Sáenz et al., 2003). Mutations in either of the genes result 
in the loss of negatively charged amino acid residues important for the interactions between 
the enzymes and nalidixic acid (Niemira, 2005). Another explanation for resistance is that 
nalidixic acid activity is known to be affected by the inoculum density (Greenwood and 
O’Grady, 1978).  
 
For a pathogen to be classified as multi-drug resistant, they must be non-susceptible to one 
agent in three or more classes of antibiotics (Arana et al., 2017). The multi-resistant E. coli 
tested in this study was found to be resistant to five antibiotics all in different classes such as 
penicillin, polymyxin, aminoglycoside, quinolone and tetracycline. Acquisition of co-
resistance is usually through mobile genetic elements such as plasmids, gene cassettes and 
transposons all in which would code for efflux pumps, enzymes that modify drugs, changes in 
target sites and changes in membrane permeability to antibiotics (Sáenz et al., 2004). 
Chloramphenicol would be the recommended antibiotic to treat infection with this particular 
strain of multi-resistant E. coli. Although EUCAST does not have data on the susceptibility of 
E. coli to streptomycin, it has been reported that strains are highly resistant to the drug (van 
den Bogaard et al., 2001). 
 
4.2 Cytometric Bead Array Analysis of Bacterially Contaminated Platelet Releasates  
Bacterial infections typically result in the production of specific pro-inflammatory cytokines 
and chemokines, leading to clearance of invading microbes. Platelets are now known to be a 
critical player in the initial recognition of bacteria, and the orchestration of subsequent 
immune responses.  Cytometric Bead Array assays were used to determine the concentration 
of cytokines and chemokines released by platelets after bacterial contamination. TNF-α, IL-6, 
IL-1β and RANTES were measured as these cytokines and chemokines are commonly 
implicated in sepsis in the proinflammatory phase (Rigato et al., 1996; Capoulade-Métay et 
al., 2006; Bester and Pretorius, 2016). Platelets primed with S. epidermidis and S. marcescens 
induced very similar cytokine profiles in which incubation with both forms of bacteria 
generated little to no TNF-α, IL-6 or IL-1β after 4 h incubation. Platelets primed with S. 
epidermidis (seven days) and S. marcescens (five and seven days) biofilms induced detectable 
TNF-α concentrations whilst their planktonic counterparts did not. Literature reported that 
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biofilm-released bacteria demonstrated higher virulence potential than their planktonic and 
biofilm-associated cells which may be one reason as to why TNF-α was detected in the biofilm 
samples (França et al., 2016). Another reason could be that TNF-α is pre-formed in the α-
granules of platelets (Limb et al., 1999) and would be immediately detected in the samples. 
IL-6 and IL-1β on the other hand, may require longer an incubation period to allow synthesis 
and detection. This was supported by the detection of IL-6 and IL-1β after 24 h.  
 
Both bacteria induced in very similar cytokine profiles after incubation with PRP for 24 h. 
However, S. marcescens produced higher concentrations of TNF-α and IL-6 compared to S. 
epidermidis. This may be due to the presence of lipopolysaccharide (LPS) in the cell wall of 
the Gram negative S. marcescens being a more potent mediator of TNF-α and IL-6 secretion. 
Another explanation for this may be that lipoteichoic acid (LTA), a cell wall component of 
Gram positive bacteria i.e. S. epidermidis, and LPS are recognised by TLR2 and TLR4 
respectively and may activate different pathways for cytokine secretion resulting in variable 
cytokine profiles. In support of this, a study demonstrated that LTA was able to induce a 
modest inflammatory response in human lungs thus indicating that a different inflammatory 
profile was generated (Hoogerwerf et al., 2008). Surprisingly, no IL-6 was detected following 
S. epidermidis biofilm treatment (established over seven days) but IL-6 was detected with the 
five-day biofilm. It was expected that the more mature biofilm would provoke a higher 
concentration of IL-6 due to higher bacterial counts thus increasing the chances of interaction 
between platelets and bacteria. This might be an anomaly or may be better explained by the 
development of a thicker extrapolymeric substance (EPS) in the seven day biofilm which 
provided better protection from immune recognition as bacterial ligands become inaccessible 
to platelets (Thurlow et al., 2011). Indeed, it is known that more established biofilms are 
effective at evading immune recognition (Le et al., 2018).  
 
It was also unexpected to find a lack of IL-1β secretion following 24h incubation with S. 
epidermidis or S. marcescens biofilms. As one of the key mediators of the inflammatory 
response, IL-1 β would be expected to be released at similar concentrations as TNF-α. 
Previous data has shown that biofilms elicited lower levels of proinflammatory cytokines by 
5- to 10-fold compared to planktonic cells (Spiliopoulou et al., 2012). It was hypothesised that 
biofilm phase bacteria weakly stimulate Th1 cells which are one of the major proinflammatory 
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cytokine secretor cells (Spiliopoulou et al., 2012). In addition, it was also observed that 
production of immunosuppressive cytokines such as IL-13 and IL-10 were increased in biofilm-
stimulated leucocytes (Spiliopoulou et al., 2012). Generally, S. epidermidis (Gram positive) 
stimulated a higher concentration of IL-1β from platelets than S. marcescens (Gram negative). 
It has been shown that Gram negative bacteria possess chemoreceptors for specific 
chemokines to enhance their growth (Di Domenico et al., 2018). The same study also 
demonstrated that Staphylococcus aureus (Gram positive) in both planktonic and biofilm 
forms was able to increase its own growth through the uptake of IL-1β and interferon- (IFN-
) in a concentration dependent manner which may explain the low concentrations of IL-1β 
for S. marcescens (Di Domenico et al., 2018). However, the validity of this in the present 
setting would require further investigation. 
 
Interestingly, levels of RANTES were significantly higher than TNF-α, IL-6 and IL-1β following 
incubation of either bacteria in both planktonic and biofilm forms. RANTES has been 
established as a chemokine therefore its upregulation is expected during inflammation to 
promote the chemotaxis of leucocytes (Bacon et al., 1995). Platelets are also known to be a 
major reservoir of RANTES (Ellis et al., 2005), therefore, this could be a potential explanation 
for its high concentration in comparison to the other cytokines measure. Another suggestion 
for this observation is that IFN- has been shown to increase RANTES expression (Pan et al., 
2000). Therefore, other cytokines present within the platelet secretome may work in synergy 
with RANTES to promote its function. Erythrocytes have been shown to inhibit RANTES-
mediated activation on a number of cells (Appay et al., 1999), thus, the absence of 
erythrocytes may result in the uncontrolled release of RANTES from platelets. 
 
Due to time constraints, CBA analysis of both E. coli strains were not carried out in this study. 
 
4.3 U937 Monocytes Surface Expression After Incubation with Bacterially Contaminated 
PRP 
The consequences of platelet and bacterial interactions leads to platelet degranulation of 
cytokines and chemokines to activate the immune response (Yeaman, 2010). As a result of 
this, surface expression of adhesion molecules and activation markers on leucocytes will be 
upregulated to allow transmigration of these cells towards the inflamed loci to exert their 
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effector functions (Lintomen et al., 2018). CD54 and CD11b are adhesion molecules that are 
constitutively expressed on many leucocytes (Shin et al., 2018). They mediate the adhesion 
between leucocytes and the endothelium and their upregulation is associated with leucocyte 
activation during infection and other clinical conditions (Latger-Cannard et al., 2004; Sheikh 
and Jones, 2008). Therefore, changes in the expression of these markers can indicate the 
potential immune response within the recipient to bacterially contaminated PCs.  
 
Collective interpretation of the data obtained when analysing the activation marker 
expression on U937 monocytes following contamination with planktonic bacteria showed 
that the platelet releasate from platelets contaminated with S. epidermidis or WT E. coli did 
not induce the upregulation of CD54 or CD11b on this cell type. However, the platelet 
releasate secreted in response to the multi-drug resistant strain of E. coli was found to vastly 
upregulate CD54, but not CD11b. Studies have shown that LPS on Gram negative bacteria is 
more potent in activating the inflammatory response compared to LTA on Gram positive 
bacteria by 100-fold (Yipp et al., 2002; Finney et al., 2012), which may provide a possible 
explanation for the difference in U937 monocyte activation status caused by S. epidermidis 
and multi-resistant E. coli. In addition to this, S. epidermidis lack typical elements that are 
usually recognised as virulence factors such as toxins (Yao et al., 2005). Its main virulence is 
characterised by its ability to form biofilms (Greco et al., 2007) therefore, this may explain the 
lack of changes in U937 monocyte activation. Some strains of S. epidermidis also possess a 
capsule which may prevent its recognition by platelet TLR2, thus there would be a lack of 
proinflammatory cytokine production to generate an immune response (Yipp et al., 2002). To 
add to this, different species of Gram positive bacteria possess LTA with different efficacies in 
stimulating TLR2, for example, Streptococcal pneumoniae LTA is 100-fold less effective than 
Staphylococcus aureus LTA in stimulating TLR2 on Chinese hamster ovary cells (Han et al., 
2003); thus suggesting that S. epidermidis LTA lack the potency to elicit U937 cell activation. 
Strain variation between WT and multi-resistant E. coli could affect the potency of LPS in 
inducing upregulation of CD54 and CD11b, in which the LPS of multi-resistant E. coli appeared 
to be a more effective activator. However, despite demonstrating a significant increase in 
CD54 expression, levels of CD11b remains unchanged with multi-resistant E. coli 
contaminated releasate. The precise mechanism behind this observation is unknown but 
some reasons for this may include secretion of cytokines that specifically upregulate CD54 
 70 
and not CD11b or that bacterial components of multi-resistant E. coli may work synergistically 
with plasma factors to regulate CD11b expression.  
 
When looking at the effect of bacterial biofilm-stimulated platelets, again CD54 expression 
was found to be significantly elevated on U937 monocytes in response to stimulation with 
platelet-releasate from platelets contaminated with the multi-resistant E. coli strain. 
Stimulation of the platelets with biofilms of S. epidermidis or WT E. coli did not have the same 
effect. CD11b expression on U937 monocytes remained unaffected following stimulation by 
platelets that had been in contact with any of the biofilm species tested. One study had shown 
that biofilms causes lower level of cell activation through a sustained release of cytokines at 
reduced concentrations compared to their planktonic counterparts (Spiliopoulou et al., 2012), 
which could be a possible explanation for the results observed for S. epidermidis and WT E. 
coli. Other potential reasons as to why there was a lack of changes in activation status with S. 
epidermidis and WT E. coli biofilms could be that previous studies have established that 
biofilms are capable of skewing the host’s immune response towards immunosuppression to 
allow its persistence (Hanke et al., 2013). In addition to this, it was shown that S. epidermidis 
was able to elicit a cytokine profile that encourages the polarisation of monocytes towards a 
M2 macrophage phenotype which possess anti-inflammatory properties and therefore, a 
decreased in the activation of U937 monocytes can be observed (Hanke et al., 2013). 
 
The reason for the upregulation of CD54 with contaminated multi-resistant E. coli releasate 
is again, not fully understood but the same reasoning with planktonic multi-resistant strain 
could be applied here. Genotypic and phenotypic changes, such as the exchange and 
upregulation of virulence factors, can occur when bacteria are within a biofilm (Jefferson, 
2004). These changes may include the ability to produce toxins by multi-resistant E. coli and 
act as a potent platelet activator induce CD54-mediated aggregation in platelets through 
specific cytokine production (Watson et al., 2016). Therefore, the cytokines produced by 
multi-resistant E. coli primed platelets could induced very similar effects on U937 monocytes. 
The ability of bacteria to form biofilms does not appear to cause any significant effect on the 
activation markers on U937 cells, instead, the antimicrobial resistance, species and strain of 
the bacteria seem to have a bigger impact.  
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4.4 HL-60 Neutrophils Surface Expression After Incubation with Bacterially Contaminated 
PRP 
Results for HL-60 neutrophils showed that planktonic S. epidermidis was able to have a more 
significant effect on the activation status than its biofilm form and more so than on U937 
monocytes. There may be some platelet activation due to the isolation protocol but the 
planktonic S. epidermidis contaminated releasate had a more significant effect on CD54 than 
plasma. Expression of CD66b was analysed in addition to CD54 and CD11b as it is a known 
granulocyte specific marker (Lakschevitz et al., 2016). Neutrophil activation was observed for 
planktonic S. epidermidis but not the biofilm. This could be attributed to the anti-
inflammatory effect of the biofilm as mentioned previously. As for the upregulation of CD54, 
both forms of S. epidermidis may work synergistically with factors in the plasma and/or 
platelet releasate to cause this effect.  
 
In contrast to U937 monocytes, WT E. coli contaminated PRP was able to activate neutrophils 
in both forms. The biofilm appeared to have a more significant effect as both CD11b and 
CD66b activation markers were upregulated.  
 
In line with the results observed for the U937 monocytes, the multi-resistant E. coli had the 
most significant effect on platelet-induced neutrophil CD54 expression, whilst CD11b and 
CD66b expression was comparable to that induced by other bacteria tested and their effects 
seen on U937 monocytes. This particular multi-resistant E. coli strain may possess the -
haemolysin toxin which could induce apoptosis, necrosis or lysis of cells (Nazareth et al., 2007). 
In agreement with this study, -haemolysin could cause the lysis of platelets and therefore, 
sudden release of its granule contents, resulting in subsequent variable surface marker 
expression. 
 
4.5 U937 Monocytes, HL-60 Neutrophils and Primary Human Neutrophil Surface Expression 
After Incubation with rhRANTES 
RANTES is classified as a C-C chemokine which was described to have a preferential effect on 
mononuclear cells, T cells and eosinophils but recent evidence has demonstrated that RANTES 
may also be involved in neutrophil migration in murine models (Ramos et al., 2005). The 
receptors for RANTES are CCR1, CCR2, CCR3, and CCR5 and have been reported to be present 
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on many leucocytes including monocytes and neutrophils (Reichel et al., 2006; Øynebråten et 
al., 2015). From this, it may be speculated that RANTES would have a biological effect on 
neutrophils. 
 
Flow cytometric analysis was carried out to investigate whether RANTES alone affected the 
activation status of the three cell lines tested. From the results, it was determined that 
rhRANTES had no effect on U937 monocytes and HL-60 neutrophils at all concentrations 
tested. However, it appeared to have some variable effect on primary human neutrophils but 
no correlation was shown between rhRANTES concentration and surface expression with the 
exception of CD66b. The effects of rhRANTES on HL-60 neutrophils also did not correlate to 
human neutrophils. These results are surprising as literature had reported that RANTES is a 
chemokine for monocytes and therefore, upregulation of CD54 and CD11b should be 
observed (Schall et al., 1990; Kameyoshi et al., 1992; Conklyn et al., 1996). There is still an 
ongoing debate whether RANTES is a chemotactic agent for neutrophils as some studies have 
reported that neutrophil activation was absent in the presence of RANTES (Rot et al., 1992; 
Conklyn et al., 1996). Others authors have described that RANTES may be a weak 
chemoattractant for neutrophils as chemotaxis was observed but only moderately (Schall et 
al., 1990; Zarbock et al., 2007; Houard et al., 2009). Others have reported an influx of 
neutrophils infiltration after RANTES expression (Pan et al., 2000; Lim et al., 2006).  
 
One potential reason for the discrepancies between literature and the results of this study 
could be that RANTES exists in variable forms which can exert different biological activities. 
Natural RANTES and rhRANTES exist in the form of 1-68 but it was discovered that it can be 
processed by proteases associated on the surface of monocytes and neutrophils (Proost et 
al., 1998; Lim et al., 2006). The 3-68 RANTES variant is produced by cathepsin G by removing 
two NH2-terminal residues and has been shown to have poor chemotactic activity on 
monocytes (Lim et al., 2006). CD26 in contrast, converts 1-68 RANTES into 4-68 RANTES 
through the removal of three residues which exhibit a 10-fold lower affinity for CCR5 and 100-
fold weaker chemotactic effect compared to the 3-68 variant (Lim et al., 2005). As such, U937 
and HL-60 cells may express high levels of CD26 and cathepsin G on their surfaces leading to 
high concentration of variant RANTES with reduced chemotactic properties. In contrast, 
human neutrophils were isolated from different donors therefore, heterogenetic expression 
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of these proteases may affect the number of available functional RANTES therefore 
significance can be found at variable concentrations of rhRANTES with no trends (Lim et al., 
2006). This may also explain the decrease in CD66b expression as the variant RANTES may 
cause an anti-inflammatory response in human neutrophils (Braunersreuther et al., 2010). 
Another possibility is that the isolation protocol cannot guarantee the complete removal of 
erythrocytes which was demonstrated to have an inhibitory effect on RANTES (Appay et al., 
1999). In addition to this, human neutrophils can rapidly degranulate during isolation (Hanke 
et al., 2013) which may cause an increase in CD66b activation but the presence of rhRANTES 
cause an anti-inflammatory effect and subsequent downregulation of CD66b.  
 
Proteolysis of RANTES is thought to regulate the inflammatory response as both truncated 
RANTES are weak chemotactic agonists and/or inhibits the function of unprocessed RANTES 
through competitive binding of CCR5 leading to immunosuppression (Struyf et al., 1996; 
Proost et al., 1998; Lim et al., 2006). In addition, it was discovered that the 3-68 variant was 
the most abundant form of RANTES and that intact RANTES may be a minor component of 
the total RANTES pool (Proost et al., 1998; Lim et al., 2006). This could suggest that intact 
RANTES may not be causing the effects observed in this study and/or that both truncated 
forms of RANTES may have more of an effect than what was originally thought.  
 
Another factor that may affect the bioactivity of RANTES is that it has been recognised that 
RANTES is able to self-associate in a concentration-dependent manner and that 
polymorphisms of the E26 and E66 residues abolishes aggregation (Appay et al., 1999; 
Czaplewski et al., 1999). The functional properties of RANTES are dependent upon its self-
aggregation as disaggregation renders RANTES non-inflammatory (Appay et al., 1999; Pan et 
al., 2000). Oligomerization of RANTES is promoted at high concentrations and by its 
interactions with glycosaminoglycans on the surface of cells which give rise to the potential 
of crosslinking with other cell surface receptors for signalling and cellular activation; 
disaggregated RANTES appears to lack this ability (Ebisawa et al., 1994; Appay and Rowland-
Jones, 2001; Øynebråten et al., 2015). The lack of changes in surface expression on U937 and 
HL-60 cells may be caused the lack of aggregation of rhRANTES or that concentrations used 
were too low to generate aggregation. In line with this, it was reported that RANTES exerts 
its bioactivity at concentrations between 40-8000 ng/mL (Cocchi et al., 1995). 
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From the results of this study, RANTES appears to have little to no effect on leucocyte 
activation and that the degree of cell activation is dependent on the bacterial contaminant, 
with the most virulent strain causing a significant increase in CD54. Whether the bacterial 
contaminant exist as a planktonic cell or biofilm does not appear to have a considerable effect 
on the activation status on U937 monocytes and HL-60 neutrophils. The implication of this 
suggest that the severity of T-AS/T-ABI might be related to the contaminating bacteria species 
ability to trigger an immune response from platelets and subsequent degranulation. RANTES 
itself may not cause the upregulation of the activation markers but may work synergistically 
with other cytokines and chemokines secreted by platelets to modulate expression. In the 
absence of bacterial contamination, the platelet releasate was able to upregulate surface 
expression of CD54, CD11b and CD66b implicating that the 273 suspected T-ABI cases 
negative for bacterial contamination may actually be caused the platelets themselves or other 
cytokines within the platelet releasate; this warrants further investigation to identify the 
causative agent (SHOT, 2015; SHOT, 2016; SHOT, 2017; SHOT, 2018).  
 
Overall, the results of this study implicate that virulence of the pathogen affects the strength 
of the immune response of platelets as multi-resistant E. coli contaminated platelet releasate 
was shown to evoke significant upregulation in activation markers in both cell lines when 
compared to WT E. coli and S. epidermidis. However, whether RANTES released from platelet 
granules were the main driver of platelet immune activity remains to be elucidated. As 
mentioned previously, it was reported that RANTES concentrations were found to be 
between 40-8000 ng/mL in addition to specific forms of RANTES has low affinity towards CCR5, 
this may explain the huge difference in concentrations between other cytokines measured. 
The lack of activity on HL-60 and U937 cells along with variable activity of rhRANTES on human 
neutrophils showed that it is probable that RANTES itself may not be responsible for the 
activation of the immune cells. Rather, TNF-α may be the main cytokine responsible for 
immune cell activation as it is known that TNF-α and its receptor, type-1 TNF-α receptor, bind 
with high affinity (Turner et al., 2010). In addition, it was also reported that some cell lines 
are sensitive to TNF-α at concentrations as low as 8 pg/mL (Khabar et al., 1995). However, 
this does not rule out the possibility that RANTES may be the main inflammatory signal as 
concentrations tested were not in the range of its optimal bioactivity.  
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The myriad of inflammatory molecules stored in intracellular granules of platelets largely 
contributes to the platelet ability to participate in the immune response. The effector function 
of platelets can be activated through direct or indirect binding of platelet PRRs such as 
complement receptors, FcRIIa, TLRs, GPIIb-IIIa and GPIb, and the pathogen (Ali et al., 2017). 
The mechanisms behind the interaction between platelets and bacteria has been reviewed 
extensively by Hamzeh-Cognasse et al. The fundamental difference between S. epidermidis 
and E. coli was its cell wall components in which LTA was found exclusively in Gram positive 
bacteria whilst LPS was found in Gram negative bacteria. LTA was reported to be less efficient 
in inducing an inflammatory response during infection than LPS and may inhibit platelet 
activation instead, which could explain the lack or minor changes observed in S. epidermidis 
contaminated PRP treated cells (Tunjungputri et al., 2016; Kang et al., 2018). However, it was 
also reported that administration of LPS to healthy volunteers did not strongly activate 
platelets however, the results of this study contrasts this as WT E. coli was able to upregulate 
activation markers in its planktonic and biofilm forms (Schrottmaier et al., 2015; Thomas et 
al., 2015). The discrepancy may be due to different E. coli strains used in the studies but 
majority of literature reported a higher inflammatory response in many infectious models 
(Yipp et al., 2002; Finney et al., 2012). Multi-resistant E. coli had the most significant effect on 
the activation status of both cell lines than the WT strain and it may be due to the plasmid 
encoding antimicrobial resistance may also encode for the protease, alpha-toxin. Alpha toxin 
acts on calpains, a family of proteases involved in signal transduction in the cell cycle, which 
subsequently leads to the cleavage of Bcl-X (a transmembrane protein involved in platelet 
survival) and eventual apoptosis of platelets (Kraemer et al., 2012). This event would lead to 
a substantial release of inflammatory molecules stored in platelet granules and potentially 
uncontrolled inflammation which may explain the significant upregulation of activation 
markers of HL-60 and U937 cells compared to WT E. coli.  
 
As with the majority of studies, the design of this study is subject to limitations. Current 
literature on RANTES mainly focus on its role as a potential treatment for HIV and its activity 
in regulating T cells (Roscic-Mrkic et al., 2003; Crawford et al., 2011; Zhao et al., 2016), as well 
as its role in neonatal-sepsis (Ng et al., 2006; Manoura et al., 2010; Kasztelewicz et al., 2016) 
rather than in the context of transfusion. Therefore, the novelty of this study makes it difficult 
to compare to other studies and whether the results observed is a representative of the 
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events that may occur within PCs. Another limitation would be the concentration of 
physiological RANTES does not appear to be established as one study reported that 
physiological RANTES was found to be at 15 – 150 ng/mL (Trenchevska et al., 2015), while 
another reported concentration to be at an average of 0.472 ng/mL (Albert et al., 2017). The 
discrepancies between the studies could be due to the methodology and sensitivity issues 
with the equipment used for measurements or that the concentration of physiological 
RANTES is highly variable between individuals. Taking this into account, the concentrations of 
rhRANTES used in this study would fall into physiological concentrations therefore, minimal 
to no change in activation marker expression would be observed, in which the study 
demonstrated with U937 and HL-60 cell lines but not primary human neutrophils. Therefore, 
it would be important to determine the activity of RANTES at physiological conditions and 
how increasing or decreasing concentration would affect cell activation.  
 
5.0 Future Work 
The focus of this study was on the effects of bacterially-contaminated platelet releasates on 
monocytes and neutrophils. It was determined that considerable concentrations of RANTES 
were secreted by platelets after bacterial contamination. However, experiments using 
rhRANTES showed no effect on U937 and HL-60 cell lines. Yet variable effects were observed 
on primary human neutrophils. This raises more questions on the exact role of RANTES on the 
activation status of innate immune cells and its mechanism of action. Further research within 
this area will deepen the understanding of how bacterial contamination would affect platelet 
activation and the consequences that would occur after transfusion.  
 
One area to look at in future work would be testing higher concentrations of RANTES than 
the ones used in this study as the minimum concentration of RANTES for it to exert its 
chemotatic activity was reported to be 40 ng/mL (Cocchi et al., 1995). Determining the 
optimal concentration of RANTES to cause adverse transfusion reaction within recipient 
would be beneficial in the potential development of a detection system that measures the 
level of cytokines within PCs for bacterial contamination to overcome the sensitivity issues 
that current bacterial detection technologies face (Jacobs et al., 2008). Another avenue to 
explore would be the possible synergistic interactions between RANTES and other cytokines 
present with the platelet releasate for a more accurate depiction of the events that might 
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occur within PCs in which complex interactions between platelets and cytokines are more 
likely to be involved than a single cytokine alone (Bartee and McFadden, 2013). 
Characterisation of the cytokine profiles evoked by different bacteria upon platelet 
stimulation would also be beneficial for further research as this study and other literature has 
shown that strain variation within a species can trigger different immune response within a 
host (Sela et al., 2018). PCR studies looking at gene expression of CD26 and cathepsin G on 
leucocytes to determine the dominant RANTES form found in the samples could explain the 
reason as to why zero to variable effects could be seen in the rhRANTES treatment, which 
may be due to differences in protease expression on immortalized cell lines and primary 
human cells. 
 
6.0 Conclusions 
T-AS and T-ABI still remains as one of the leading causes of morbidity and mortality in 
transfusion recipients with bacterially contaminated PCs being the most frequently 
implicated blood product. Even with the advancement of the automated BacT/ALERT® 
microbial detection system, contaminated PCs can bypass screening tests due to initial low 
inoculums and consequently cause adverse transfusion reactions. Indeed, in over half of 
suspected T-ABI/T-AS cases in which the patients are showing obvious clinical symptoms, 
subsequent microbial follow-up investigations report culture negative or inconclusive. This 
raises the question on whether these T-AS/T-ABI clinical symptoms are caused by direct 
interaction of the bacteria themselves, or by bacterially-primed platelets.  
 
CBA analysis demonstrated that the chemokine RANTES was secreted at highly significant 
concentrations in comparison to IL-1β, IL-6 and TNF-α when PRP was incubated with S. 
epidermidis and S. marcescens regardless of incubation times and/or whether the bacteria 
exist as planktonic cells or biofilms. These results suggest RANTES may play a key role in the 
initiation of the host immune response if the contaminated PC were to be transfused. Further 
investigations revealed that bacterially primed platelet releasates primed by either planktonic 
or biofilm forms of S. epidermidis and WT E. coli had no significant effect on the expression of 
CD54, CD11b and CD66b (HL-60 cells only) in U937 monocytes or HL-60 neutrophils. Yet 
following priming of platelets with planktonic or biofilm forms of multi-resistant E. coli, the 
platelet releasate caused significant upregulation of CD54 expression in both cell types. It is 
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suspected that this effect can be attributed to its virulence. Indeed, ZoI assays showed that 
multi-resistant E. coli was the least susceptible to antibiotics followed by S. epidermidis and 
WT E. coli. However, the precise mechanism behind this upregulation of CD54 activation 
marker is not fully understood. It must also be noted that plasma, free from bacterial 
contamination, was able to upregulate surface expression on both cell lines but this was only 
to a very moderate degree. It could however, suggest that proteins within the bacterially-
primed plasma itself could contribute to the immune activation in T-AS. 
 
Incubation of rhRANTES with U937 and HL-60 cells did not induce any significant changes in 
the expression of CD54, CD11b and CD66b. However, it appeared to have a variable effect on 
primary human neutrophils. Previous literature has stated that proteases on the surface of 
leucocytes are responsible for post-translational changes to many cytokines, including 
RANTES, giving rise to variable forms with different biological activities and efficacies. This 
may explain the inconsistent expression of CD54 and CD11b on primary neutrophils. Curiously, 
CD66b expression however, appears to be downregulated as rhRANTES increases.  
 
In summary, despite its significantly upregulated release from bacterially primed platelets, 
RANTES itself may not be the sole chemokine that stimulates the expression of activation 
markers on innate immune cells as results from this study demonstrated variable effects. The 
type of bacterial contaminant does appear to play a key role in inducing the secretion of 
varying concentrations of specific cytokines from platelets that generate different degrees of 
activation of leucocytes. However, further investigation is warranted to elucidate the precise 
mechanism of action that causes these changes.  
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